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ABSTRACT
THE EFFECT OF TREATMENT DELAY, NON‐ADHERENCE TO TREATMENT GUIDELINES, AND
NEVER‐SMOKING STATUS ON THE SURVIVAL OF LUNG CANCER PATIENTS
Trisari Anggondowati, MPH
Supervisor: KM Monirul Islam, MD, MPHD, Ph.D.
Despite many significant medical advances, lung cancer continues to cause more deaths than
any of the other cancers in the United States (US), and worldwide. Timeliness of care and
evidence‐based guidelines are among the components of quality of care that are expected to
improve patient outcomes. However, evidence on the effect of timeliness of care and adoption
of evidence‐based guidelines on patient survival remains lacking. In addition, there has been
increasing concern on the fact that smokers are not the only group that suffers from lung cancer.
Never‐smokers comprise at least 10% of lung cancer patients in the US, or 25% worldwide. A
better understanding of outcomes among never‐smoker patients is needed. Using two
nationwide cancer registries, this dissertation examines the effect of extended time‐to‐treatment,
non‐adherence to treatment guidelines, and never‐smoking status on the survival of lung cancer
patients. The results of our study suggest the harmful effect of extending time to treatment
initiation among patients diagnosed with early stage cancer and resectable lung tumor, and the
survival benefit of adherence to treatment guidelines. This study also highlights the importance
of ensuring never‐smoker patients received molecular testing and targeted therapy since the
survival benefit among never‐smokers was only evident in patients diagnosed at younger than 65‐
years‐old. Overall, the results of this dissertation could assist in improving the provision of lung
cancer treatment, which would lead to improved patient outcomes.
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CHAPTER I: INTRODUCTION
1. LITERATURE REVIEW
1.1 Background
1.1.1 Epidemiology of lung cancer
Lung cancer remains a significant public health problem worldwide, being the second most
common cancer. Approximately 55% of lung cancer cases occur in Asia, but the incidence rate is
highest in North America.1 In the United States (US), lung cancer is the second most common
cancer after prostate cancer in males and breast cancer in females (excluding non‐melanoma skin
cancer).2 The Surveillance Epidemiology and End Results (SEER) program reported an age‐
adjusted incidence rate of lung cancer of 55.8 per 100,000 persons between 2010 and 2014.3 The
incidence rate of lung cancer per 100,000 persons is higher among males (65.7) than females
(48.4) and higher among black (63.0) than white (57.3) patients. Gender variations in lung cancer
incidence are largely attributed to the different patterns of tobacco smoking and cessation
between men and women.2,4
Lung cancer has remained the leading cause of cancer deaths since the 1950s in men and
since the late 1980s in women.5 In 2018, an estimated 234,030 people will be diagnosed with lung
cancer in the US, and 154,050 will likely die of the disease. Although the mortality rate from lung
cancer has decreased since the 1990s, lung cancer still accounts for 1 in 4 cancer deaths. Lung
cancer‐related deaths exceed the total number of deaths associated with colon, prostate, and
breast cancer combined.2
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According to the National Center for Health Statistics, the overall age‐adjusted mortality rate
from lung cancer over the period 2010–2014 was 44.7 per 100,000 persons.3 The mortality rate
per 100,000 persons is higher among males (55.9) than females (36.3) and among individuals aged
65 years and older (268.5) than individuals younger than 65 years (12.4). The overall difference in
mortality between whites and blacks is relatively modest (45.5 vs. 48.0 per 100,000). However,
black men have substantially higher mortality rates than white men (68.0 vs. 55.9 per 100,000).
On the contrary, black women have slightly lower mortality rates than white women (34.6 vs. 37.5
per 100,000).3

1.1.2 Risk Factors for Lung Cancer
Tobacco smoking is the leading cause of lung cancer, as between 85% and 90% of lung cancer
incidence is attributable to smoking.6 However, the fact that lung cancer also occurs in never‐
smokers emphasizes the importance of other risk factors in the etiology of lung cancer. The
following section describes the association between some of the known risk factors and lung
cancer incidence.
Smoking – Active tobacco smoking is the strongest behavioral risk factor associated with lung
cancer. A review of published studies reported that the risk of lung cancer in smokers is 20‐times
higher than in lifetime never‐smokers.7,8 The risk of lung cancer in smokers, however, depends
largely on the duration of smoking and the number of cigarettes smoked.7 Cigarette smoke
contains more than 60 carcinogens.9 Polycyclic aromatic hydrocarbons, which are the most
carcinogenic compounds present in tobacco smoke, induce mutations in the p53 gene that are
crucial for cell cycle dysregulation and the pathogenesis of lung cancer.9 The tobacco‐specific
nitrosamine, known as nicotine‐derived nitrosoaminoketone (NNK), is another major group of
chemical substances found in tobacco smoke.5
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Environmental exposures – There has been a growing body of literature suggesting the
importance of environmental exposures, both indoor and outdoor, on lung cancer risk. The
International Agency for Research on Cancer (IARC) has evaluated biological and chemical
substances with respect to the cancer risk that those substances pose. For example, radon,
secondhand tobacco smoke, asbestos, indoor emissions of coal from household combustion, and
outdoor pollution are categorized as Group 1, which consists of carcinogens that affect humans.
Indoor emission of biomass fuel is categorized as Group 2A (probably carcinogenic to humans).10
Radon has been established as the second leading cause of lung cancer in the US after tobacco
smoking by the Environmental Protection Agency.11 In a meta‐analysis of 22 studies, of which 19
of them were conducted in Europe and North‐America, Zhang et al. estimated a pooled Odds
Ratio of lung cancer of 1.29 (95% CI, 1.10‐1.51) between the highest and lowest exposure of
residential radon. The dose‐response analysis showed an increased by 7% for every 100 Bq/m3
increment in residential radon exposure (95% CI, 1.04‐1.10; P for trend < 0.001).12
Genetics and family history – The fact that only a small percentage of smokers are diagnosed
with lung cancer suggests that there is variation in individuals’ susceptibility to tobacco
carcinogens or other environmental exposures. One possible explanation is associated with the
differences in DNA repair capacity. Individuals with lower DNA repair capacity tend to have a
higher risk of lung cancer resulted from DNA‐damaging carcinogens.13
A pooled analysis of 24 case‐control studies from the International Lung Cancer Consortium
showed increased risk of lung cancer associated with a family history. A 1.5‐fold increased risk
was evident among individuals with a first‐degree relative with lung cancer, compared to those
without a family history, after adjusting for smoking and other potential confounders (95% CI,
1.39–1.63). A greater association between family history and lung cancer was observed among
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patients with a history of lung cancer in a sibling (OR, 1.82 [95% CI, 1.62‐2.05]) than lung cancer
in a father (OR, 1.25 [95% CI, 1.13‐1.39]) or mother (OR, 1.37 [95% CI, 1.17‐1.61).14
Age and Gender – The risk of lung cancer has been reported to be higher among older
individuals and women.5,15 Lung cancer risk increases as age advances.7 According to the
Surveillance, Epidemiology and End Results (SEER) program, the age‐adjusted incidence rate of
lung cancer among individuals aged 65 years or older in 2010–2014 was 328 per 100,000
population.3 Increasing risk of lung cancer in the older population has been associated with the
cumulative effect of tobacco‐induced carcinogens over a long period, as well as declining
physiological function. The lung cancer incidence rate is low in people younger than 40‐years‐old
(for instance the incidence among people 35–39‐years‐old is 2.7 per 100,000 population),4 but
there has been concern about its increasing incidence in this age group.7
The difference in lung cancer risk by gender remains inconclusive. Analysis of cancer registry
data analysis found that the age‐adjusted incidence rate of lung cancer is higher among men.3
This higher rate among men than women has been associated with the difference in tobacco
smoking trend over decades, which started earlier among men than women.3 The incidence rate
data from cancer registry, however, are not adjusted by smoking. Emerging evidence controlling
for the effect of smoking suggests that women are more susceptible to the carcinogenic effects
of tobacco smoking than men. 16 A large population‐based screening program found that women
were twice as likely to be diagnosed with lung cancer as men, after adjusting for the smoking
level.17

1.1.3. Clinical Presentation of Lung Cancer
The majority of patients who are diagnosed with lung cancer present with symptoms.18 However,
most early‐stage lung cancers are asymptomatic.19 By the time symptoms occur, the cancer has
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typically progressed to a more advanced stage.19 Symptoms of lung cancer, such as shortness of
breath, cough, chest pain, hoarseness, and hemoptysis, can be directly caused by the primary
tumor. Some patients, however, may present symptoms that are non‐specific, such as fatigue,
anorexia, and weight loss.20 The wide range of symptoms of lung cancer, especially non‐specific
symptoms, might not alarm patients to seek medical care and may, therefore, potentially lead to
a delay in diagnosis.19
In general, lung cancer can be divided into two major histologic types (non‐small cell lung
cancer [NSCLC] and small‐cell lung cancer [SCLC]). NSCLC is the most common type and constitutes
between 80% and 85% of all lung cancer cases.2 NSCLC includes various histologic types, with the
most common being adenocarcinoma and squamous cell carcinoma. SCLC, which accounts for
15–20% of all lung cancer cases, is a neuroendocrine tumor with cells that are smaller in size than
most other cancer cells.20 This cancer grows faster than NSCLC and metastasizes rapidly to other
parts of the body. Some lung cancer tumors contain cells that are both SCLC and a form of NSCLC
or contain more than one type of NSCLC.18 NSCLC is divided further into multiple sub‐types. The
common sub‐types are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.20
The histologic sub‐type is an important factor in determining chemotherapy agents.21
Cancer stage upon diagnosis guides treatment planning and also serves as a strong
prognostic factor. In general, NSCLC staging is determined during either clinical or pathologic
stages. The clinical stage is defined based on physical exams, biopsies, imaging tests, and other
tests, while the pathologic stage is complemented by results of surgery, if the patient underwent
surgery. When both sets of information are available, the pathologic stage is typically more
accurate.18 Lung cancer is mostly staged based on the American Joint Committee on Cancer (AJCC)
TNM system, which involves: 1) T: The size of the primary tumor, 2) N: The spread of the tumor
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to nearby (regional) lymph nodes, and 3) M: The extent of cancer spread to other organs of the
body (metastasis).22
NSCLC is typically classified into four different stages (stage I—IV). Stage I is when the tumor
size is no more than 5 cm and has not grown into nearby tissues. The tumor also has not spread
to the lymph nodes or other parts of the body. This cancer is usually referred as early‐stage cancer.
Stage II and III have more extensive criteria that involve a different level of the TNM.23 A patient
is diagnosed with stage IV disease (often referred as advanced or metastatic cancer) when the
cancer has spread to distant lymph nodes or other organs or parts of the body, such as the liver,
bones or brain. A detailed classification according to the 8th Edition Staging from the AJCC is
presented in Appendix A.
SCLC is commonly staged by the extent of the cancer spread. Limited‐stage SCLC describes
cancer that is only on one side of the chest, and extensive‐stage SCLC refers to cancers that have
spread widely throughout one lung, to the other lung, and lymph nodes on the other side of the
chest or other parts of the body.23

1.1.4 Diagnosis
In general, the diagnostic process would involve a combination of collecting tumor samples
for pathologic examination and imaging tests. For most types of cancer, a biopsy is done to take
a small sample of the tumor tissue for laboratory testing to determine whether the tumor is
cancerous and classify its histological type(s). Other procedures include bronchoscopy and needle
aspiration, or more invasive procedures, such as mediastinoscopy and thoracotomy. An imaging
test is intended to help doctors determining the size and location of the primary tumor and
metastasis. The tests include CT scans, positron emission tomography (PET) scans, and magnetic
resonance imaging. Patients with lung adenocarcinoma are also recommended molecular testing
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to identify gene mutations. Results of the molecular testing will determine whether or not
patients require therapy targeted to specific gene mutations (targeted therapy).18

1.1.5 Treatment
Cancer stage at diagnosis is a major driver of treatment options. Other factors, such as
comorbidities and performance status, help to determine a patient’s fitness for receiving
treatment. Table 1 describes the treatment modalities by cancer stage for each NSCLC and SCLC,
as recommended by the National Comprehensive Cancer Network (NCCN).
Table 1. Recommended treatment of lung cancer
Stage

Recommended treatment
NSCLC

Stage I

Stage II
Stage IIIA
Stage IIIB
Stage IV

Limited stage
Extensive stage

 Surgery
 Patients with a high risk of recurrence (based on size, location, or other factors) may
be recommended for adjuvant chemotherapy after surgery
 Surgery
 Patients are recommended for adjuvant chemotherapy after surgery
 Include combinations of radiation therapy, chemotherapy (chemo), and/or
surgery.
 Chemotherapy combined with radiation therapy when patient’s overall health is good.
Otherwise, the treatment would be either radiation therapy or chemotherapy
 Non‐curative surgery, chemotherapy, targeted therapy, immunotherapy, or radiation
therapy, depending on patients’ condition
SCLC
 Chemotherapy combined with radiation therapy
 Chemotherapy

Source: NCCN Clinical Practice Guidelines in Oncology24,25
Most patients with stage I and some stage II patients can potentially receive curative
treatment with surgery. Adjuvant chemotherapy is given for stage I and II patients who are
deemed at high risk of recurrence. Patients with stage III NSCLC are usually treated with a
combination of chemotherapy and radiotherapy. In some patients with stage IIIA NSCLC, the
treatment might also include surgery. Patients diagnosed with stage IV have had their cancer
metastasized, and thus, cure is not usually the goal of the treatment. Most of stage IV patients
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receive systemic therapy, and only if they are in good health, they may undergo surgery and
radiation therapy to relieve their symptoms.23
Treatment decision‐making for SCLC is complex. A patient with limited‐stage cancer without
any metastasis to the lymph nodes might be recommended for surgery, followed by
chemotherapy.26 However, such a case is rare because cancer has typically spread by the time it
is detected. If the cancer is found in the lymph nodes, the patient may receive chest radiotherapy,
which is often given simultaneously with chemotherapy. While this approach is more effective
than giving one treatment after the other, the simultaneous application of radiation and
chemotherapy increases the side effects of the treatment.26,27 On the other hand, extensive‐stage
SCLC has typically metastasized widely, rendering surgery or radiation therapy ineffective.
Patients with extensive‐stage SCLC often receive chemotherapy to shrink cancer, treat symptoms,
and extend survival. However, some patients might be unable to tolerate the side effects of
standard doses of chemotherapy and are accordingly recommended to receive lower doses of
chemotherapy or palliative care only.27,28

1.1.6 Survival of Lung Cancer Patients
Despite the advances in medical technology and improvements in the survival rates of early‐stage
lung cancer, the survival of all stages combined remains low.3 Less than half of the patients (44%)
survive at least one year after diagnosis, and 5‐year survival rates are substantially lower (18.1%).
Fifty‐seven percent of patients are diagnosed at an extensive stage, for which the 5‐year survival
rate is less than 5%.3 Figure 1 illustrates the 5‐year survival rate by stage at diagnosis based on
data from the SEER program.3
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Figure 1. Five‐year survival (percent) by stage at diagnosis, SEER 2007–2013

Based on 2013 estimates, 22.2% of women with lung cancer survived for at least 5 years,
which exceeds the 15.6% 5‐year survival rate among men.3 The higher 5‐year survival rate among
women was consistent across all stages at diagnosis.3 The reasons for better survival in women
remains unclear. However, the fact that more women present with lung adenocarcinoma at a
younger age at diagnosis might contribute to their better outcomes.7,21 A large multi‐center study
of lung cancer patients with stage III and IV diseases in Germany found that women were nearly
twice as likely to have Epidermal Growth Factor Receptor (EGFR) mutations than men (OR,1.85
[95% CI, 1.48–2.32]) and EGFR mutations have been reported to lead to a better prognosis.29
Hormonal factors might be the only definite difference between women and men, with estrogen
receptor α and  being among the prognostic factors in lung cancer.30
Racial disparity in survival has been observed between African Americans and whites.31,32 A
later stage at diagnosis and lack of access to care have been reported to be potential contributors
to this disparity.33 A study demonstrated that the racial disparity diminished when the analysis
was adjusted for receipt of evidence‐based treatment.33 Ganti et al. (2014) reported that racial
disparity in survival was not evident within the Veterans Affairs (VA) health system, a single‐payer
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system with universal health care. In this population, African Americans exhibited slightly better
survival rates than whites.34
In the next sections, we will discuss treatment‐related factors that are associated with patient
survival, as well lung cancer in specific populations (never‐smokers and Veterans), as the focus of
this dissertation.

1.2 Treatment Delay
1.2.1 Recommended Diagnosis‐to‐Treatment Interval
A patient's journey through lung cancer care trajectories can extend over a long period. Delay in
any interval within this continuum potentially puts patients at a higher risk of more advanced
disease progression, and subsequently a poorer prognosis.35 At the very least, a delay could
increase the psychological distress of patients and their families.36,37
Clinical recommendations of time to initiate treatment varies between countries. In summary,
however, existing guidelines outlined that diagnostic testing should be completed between 2 and
4 weeks after a patient consulted a specialist, and treatment should be initiated no more than 4
weeks after diagnosis. Table 2 summarizes the recommended time‐to‐treatment from several
countries.38,39 Unlike those countries, the US does not have established guidelines pertinent to
recommended time‐to‐treatment for cancer care. In 2000, RAND Health (US) issued a proposed
recommendation of treatment initiation for NSCLC other than metastatic cancer within 6 weeks
of diagnosis.40 The recommendation was formulated based on an extensive review of the
literature by an expert panel.40
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Table 2. Existing guidelines on the diagnosis‐to‐treatment interval
Country
Sweden41

The United
Kingdom38

Canada42

Recommendation
In at least 80% of patients:
 Diagnostic tests should be completed within 4 weeks from consultation with a chest
physician
 Treatment should be started within 2 weeks after consultation with a chest physician
 Radical radiotherapy should start within 2 weeks after it is requested
 The maximum time interval between the general practitioner consultation and the
treatment is 62 days
 A maximum wait time of 1 month from diagnosis to treatment for all cancers
 A maximum of 4 weeks from the first visit to a family physician to diagnosis
 Waiting time from completion of diagnostic tests to surgery should not exceed 2
weeks

1.2.2 Treatment Delay among Lung Cancer Patients
Treatment delay is not uncommon among cancer patients. Between 28.0% and 56.7% of lung
cancer patients experience treatment delays.43‐45 Using data from SEER‐Medicare, Nadpara et al.
(2011) illustrated the average time necessary for a patient to go through the lung cancer care
trajectories (Figure 2).46 On average, it takes a total 212 days, or approximately 7 months, for
Medicare beneficiaries with incident of lung cancer to begin treatment since a symptom is
evaluated. The median interval from the time a patient sees his/her provider for symptom
evaluation until lung cancer is diagnosed is 187 days. This is the longest time interval that a patient
should go through since it involves multiple examinations (chest X‐ray, referral by a primary
physician to the specialist, and diagnostic procedures). This symptom‐to‐diagnosis interval time
could, in fact, extend up to 308 days. The next is the diagnosis‐to‐treatment interval, which on
average takes up to 25 days (IQR = 33 days). Patients who undergo surgery would have to wait
longer (33 days), compared to those who receive radiation therapy and chemotherapy (22 and 25
days, respectively).46 It should be noted that these data were collected among Medicare
beneficiaries. Uninsured patients are likely to wait longer to begin treatment. Risk factors for
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treatment delays include older age, black race, higher comorbidity score, early or localized stage
of cancer, and high‐volume facilities.43,44

Figure 2. Time to diagnosis and treatment among continuously enrolled Medicare Fee‐for‐
service beneficiaries with an incident lung cancer diagnosis in the United States,
2003–2006

Reprinted from Nadpara et al., 2015 with permission from Elsevier.46

1.2.4 Impact of Treatment Delay on Patients’ Survival
Despite the fact that studies pertaining to the association between treatment delay and
outcome are increasing in prevalence, the results remain unclear.39 Many studies did not
demonstrate a significant negative effect of treatment delay on survival,47,48 and others found that
prolonged delay is linked with better survival.41,49 A possible explanation for the latter findings is
the fact that patients with more severe disease burden tend to experience shorter waiting times
between diagnosis and treatment. Hence, disease severity might modify the effect of delay on
patient outcomes. From a methodological standpoint, most previous studies were limited in size,
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which precluded an analysis of the data stratified by disease severity. This limitation is even
complicated by the variation in the definition of treatment delay used in existing studies (as
illustrated in Table 3), making comparisons between studies challenging.39 Table 3 describes the
definitions of delay used in several previous studies.
Table 3. Definition of delay used in several past studies
Study
Samson, et al.
201545
Gomez, et al. 201544

Location
The US

Data source
NCDB and another single‐
site hospital‐based study
SEER‐Medicare and Texas
Cancer Registry‐Medicare

Definition of delay
Resection 8 weeks or greater from the
time of diagnosis.
More than 35 days after diagnosis.

Yorio, et al. 200948

The US

Multi‐sites hospital‐based
study

Sweden

Two sites hospital‐based
study

Image‐to‐treatment interval.
Several categorizations were used:
1. < 30; 31–60; 61–90; ≥ 91
2. 42 days (Swedish Lung Cancer Study
Group)
3. 98 days (RAND Corporation)
Two types of delay:
1. Symptom‐to‐treatment delay
2. Hospital delay (the length of time
from the first hospital visit to the
start of treatment)

Myrdal, et al. 200441

The US

Interval is analyzed as continuous and
categorical variables separately (< 1 mo;
1–2 mo; 2–3 mo; and > 3 mo)
Diaconescu, et al.
Canada
Single site hospital‐
The interval between the date of the
201149
based study
first abnormal radiology that was
suspicious for lung cancer and the dates
starting treatment. The delay is analyzed
as a continuous variable.
Scotland Scottish Cancer Registry
More than 34 weeks interval from
Murchie, et al.
presentation to treatment.
201447
*all studies were on NSCLC, except for Murchie et al. (2014) who studied colorectal cancer

To the best of our knowledge, there have been only three large studies that demonstrated a
positive association between treatment delay and survival. An analysis of 28,732 NSCLC patients
from the SEER‐Medicare and Texas Cancer Registry (TCR)‐Medicare databases revealed that
adherence to the recommendation of the diagnosis‐to‐treatment interval was associated with
improved survival in patients with localized disease (aHR, 0.86 [95% CI, 0.80–0.91]). On the
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contrary, adherence was associated with poorer survival for patients with metastatic cancer who
died within 1 year (aHR, 1.35 [95% CI, 1.28–1.42]).44 Among 27,022 stage I NSCLC patients
receiving surgical resection in the National Cancer Data Base (NCDB), each week of delay to
surgery increased the hazard for mortality by 0.4% (aHR, 1.004 [95% CI, 1.002–1.007].45

1.3 Adherence to Treatment Guidelines
1.3.1 Clinical Practice Guidelines in Cancer Care
Clinical practice guidelines help to translate research findings into evidence‐based clinical
practice, guiding decision making in the complex field of cancer care.50 The Institute of Medicine
defined clinical practice guidelines as “Statements that include recommendations intended to
optimize patient care that is informed by a systematic review of the evidence and an assessment
of the benefits and harms of alternative care options.” (IOM, 2011, p. 4)51
A review by von Dincklage et al. (2013) identified 31 lung cancer guidelines published between
2008 and 2013 by 19 organizations within and outside the US.52 In the US, one of the largely
adopted guidelines in oncology is the CPGs established by the National Comprehensive Cancer
Network (NCCN). The NCCN‐issued guidelines are developed and updated by more than one
thousand clinicians and oncology researchers from the 27 leading cancer centers that are part of
the NCCN.
1.3.2 Factors Associated with Adherence to Clinical Practice Guidelines
According to IOM’s report, the translation of evidence‐based recommendations into clinical
cancer care remains slow and limited.51 Non‐adherence to CPGs can be affected by both provider
and patient‐related factors. From providers’ level, the lack of comprehensive systematic review
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in the development of the guidelines might result in different guidelines being developed for a
particular field, causing conflicting advice and could lead to non‐adoption of the CPGs. The review
by Dincklage et al. showed that nine of the 31 published guidelines were either developed without
the basis of systematic reviews or lacked information about the development method.52 IOM also
noted limitations in the monitoring and measurement process of the implementation of the
clinical guidelines.51 At patient level, age, comorbidities, and economic factors are among the
independent characteristics that predict adherence to guidelines.53,54
1.3.3 Impact of Clinical Practice Guidelines on Patients’ Outcome
In general, successful implementation of clinical practice guidelines could potentially improve
healthcare quality and patient outcomes.51,52 For instance, a study of colorectal cancer suggested
that non‐adherence to treatment guidelines in patients with stage III disease was associated with
an 80% increase in the risk of death compared with patients whose treatment adheres to the
guidelines.53

1.4 Lung Cancer in Never‐Smokers
1.4.1 Epidemiology of Lung Cancer in Never‐Smokers
Given the large share of preventable cases of lung cancer, tobacco cessation has been the central
issue of lung cancer control. However, an estimated 15% of lung cancer cases in men and 53% in
women, or equal to 25% of lung cancer worldwide are not attributable to active tobacco smoking.6
In the US, at least 1 in 10 lung cancer cases occur among never‐smokers.6,55 The term never‐
smokers refers to individuals who have never smoked or who have smoked fewer than 100
cigarettes over their lifetime.56,57 When non‐tobacco‐related lung cancer deaths are considered
to be a single category, this type of cancer ranks between the 6th and 8th leading cause of cancer
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deaths in the US, taking the lives of 16,000–24,000 people per year.58,59 This fact makes lung
cancer in never‐smokers a significant public health burden.
Although it remains unclear whether there is an increasing trend in the incidence of lung
cancer among never‐smokers (LCINS), a study analyzing cohorts and registries data between 1959
and 2004 did not observe an increase in the US.60 However, a large cohort study among male
never‐smokers in Sweden suggested a significant increase in incidence of LCINS from 1.5 per
100,000 persons in 1976–1980 to 5.4 per 100,000 persons in 1991–1995.61 Findings pertinent to
the epidemiology of LCINS have been inconclusive and geographically varied, but a number of
studies have shown that the incidence of LCINs is higher among females, African Americans, and
Asians, and that the death rate is higher among males.57,58 In terms of age at diagnosis, two
systematic reviews suggested that studies in Asian countries reported that never‐smokers tend
to be diagnosed at a younger age than ever‐smokers while studies in Western countries found the
opposite or no difference in age at diagnosis by smoking status.13,57 Based on the clinical profile,
adenocarcinoma is the most frequent histologic type among LCINS.13,62

Despite the importance of LCINS and the growing interest in research in this area over the last
two to three decades, it is difficult to ascertain the actual incidence data because most
population‐based registries do not collect information on smoking status. Existing estimates in
the US were derived mostly from a few cohort studies and a limited registry of a specific
population.60,63 The estimated incidence rates of LCINS are presented in Table 4. A number of
studies have attempted to investigate the risk factors and outcomes of LCINS. However, most of
the studies are hospital‐based, with small sample size. An improved understanding of the
incidence and etiology of LCINS could assist in designing lung cancer prevention and control
strategies.
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Table 4. Age‐standardized incidence rates of lung cancer among never‐smokers in the US
Source

Years of
follow‐up

1. Connecticut Tumor Registry (CT)

1935–1940

2. Nurses’ Health Study (NHS)
3. Health Professionals Follow‐Up Study
(HPFS)
4. California Teachers Study (CTS)

1976–2002
1986–2002

5. Multiethnic Cohort (MEC) Study

1995/1996
to 2002
1993/1996
to 2001
1971/1975
to 1992

Age‐standardized incidence rates,
per 100,000 person‐years (95% CI)
Female
Male
8.5
N/A
(95% CI not available)
15.2 (9.1–24.5)
N/A
N/A
11.2 (6.5–19)
20.8 (13.5–31.2)

N/A

20.7 (13.5–31.1)

13.7 (9.0–21.5)

6. First National Health and Nutrition
12.7 (10.2–18.2)
19.3 (14.2–27.5)
Examination Survey Epidemiologic
Follow‐Up Study (NHEFS)
7. Cancer Prevention Study II, Nutrition 1992–2003
17.1 (11.8–22.3)
11.4 (8.3–14.6)
Survey (CPS‐II Nutrition)*
8. Women’s Health Study (WHS)*
1993–2006
9.4 (5.7–13.1)
N/A
*Incidence rates were calculated only for European descents due to a very limited number of cases of non‐
European descents.
**Age of subjects were 40–79 years, except for CT (40–69 years).
Source: Wakelee et al., 200763

Radon and secondhand smoke are major contributors for LCINS in the US.64 Other exposures,
such as asbestos, arsenic, air pollution, diesel exhaust, and household cooking fumes, have also
been shown to be associated with an increased risk for the disease in studies conducted in Asia.65
A systematic review of studies among never‐smokers reported an increased risk of LCINS by 26%
(95%CI, 1.07–1.47) associated with secondhand smoking, and an increased risk by 40% (95% CI,
1.17‐1.68) associated with family history of lung cancer.57 Genetic susceptibility also plays a role
in the development of LCINS.57
1.4.2 Pathology of Lung Cancer in Never‐Smokers
Anatomically, the lung can be divided into central and peripheral compartments (Figure 3).13
According to Sun et al. (2007), tobacco‐induced lung cancer occurs in both central and
peripheral airways. Lung cancer in never‐smokers, however, typically occurs in the peripheral
compartment.13 Tumors in the peripheral compartment frequently asymptomatic, and thus,
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might not be detected at early stages.66 In addition, tumors in the peripheral airways are more
likely to metastasize to regional lymph nodes and distant sites since they are located closer to
the blood circulation.66
Figure 3. Lung anatomical compartments

Reprinted from Sun et al., 2007 with permission from Nature Publishing Group.13

1.4.3 Outcomes of Lung Cancer in Never‐Smokers
Lung cancer in never‐smokers has major clinical implications. A large proportion of never‐smokers
diagnosed with lung cancer harbor genetic mutations that are responsible for the initiation of lung
cancer and affect sensitivity to treatment.59 Epidermal Growth Factor Receptor (EGFR), EML4‐ALK
fusion, and deregulation of MET signaling are the commonly identified genetic abnormalities.67
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EGFR mutations are more frequent among never‐smokers than smokers. The clinical implication
is that never‐smokers tend to have a better response to treatment with EGFR small molecule
inhibitors, and thus, are expected to have a higher survival rate than ever‐smokers, although the
results have been inconsistent.67 The differences in the clinical features of lung cancer between
never‐smokers and ever‐smokers suggest the need to consider LCINS as a separate entity.62

1.5 Lung Cancer in Veterans
In general, compared with the general population, the incidence of lung cancer is higher, and
survival is poorer, among veterans, although the overall results have been inconsistent.68‐70
Among the veteran population, the higher incidence of lung cancer is associated with higher rates
of smoking compared to the general population. Additionally, veterans who smoke tend to be
heavy smokers.71 And thus poorer survival has been linked with high comorbidities. Data from
1970–1982 shows that the incidence rate of lung cancer among males in the Veterans Affairs (VA)
health system was 76% higher than the estimate from the SEER Cancer Registries.69 An analysis of
the Pennsylvania Cancer Registry found that 5‐year survival among veterans with lung cancer was
12%, lower than among civilians (15%).68 In contrast, another study found that survival was better
among patients in the VA health system compared with non‐VA patients, which could be
explained by diagnoses at earlier stages among VA patients as a result of better access to care.70
The veteran population is unique not only due to their distinct demographic characteristics
but also exposure to various risk factors other than smoking, which is likely to be at a higher level
than that of the general population. The known risk factors among this population include Agent
Orange, radon, asbestos, depleted uranium used in weapons and armor shielding, beryllium, fuel
exhaust, and other battlefield emissions. Therefore, it is reasonable to expect that the incidence
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of lung cancer in never‐smokers in this population will be higher than the incidence in the general
population.
To the best of our knowledge, the only available estimate for lung cancer among non‐smoking
US Veterans is the mortality rate from Dorn’s study conducted among male veterans in 1955–
1969.72 The death rates of lung cancer in non‐smoking male veterans varied between 13.4 and
19.6 per 100,000 persons in this study.72 In comparison, the death rates for never‐smoking males
in the general population was 18.7 per 100,000 persons for 1959–1972 and 17.1 per 100,000
persons for 1982–2000.58

2. SUMMARY OF RESEARCH GAPS
The persistently high mortality of lung cancer has led to a number of studies aiming at
understanding the prognostic factors of lung cancer. Nevertheless, it remains unclear how some
of those factors are associated with the survival of lung cancer patients, which this dissertation
tries to address.

2.1 Time‐to‐Treatment in Lung Cancer Patients
Delayed treatment has been hypothesized to be associated with decreased patient survival.
However, findings from studies of multiple cancers show mixed results. Several studies confirmed
this hypothesis,47,73 while other studies reported contrasting results.41,49 Evidence from studies in
lung cancer patients has been limited and inconclusive. Our review of the literature identified
three US studies that showed a significant increase in mortality risk associated with treatment
delay in patients with NSCLC. These studies, however, have several limitations. One study was
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restricted to elderly patients (aged 66 years and older) who were Medicare beneficiaries, and
thus, the generalization of the findings was limited.44 As older age is an independent, strong
predictor of survival, the question remains whether the effect of treatment delay is independent
of age. The other two studies investigated the effect of delay only in surgery, and thus, further
investigation is needed to determine whether the negative effect of delay also presents in
patients receiving other treatment modalities.45,73 Most of the remaining studies in lung cancer
reported counter‐intuitive results, of which a longer time‐to‐treatment was associated with
improved survival; a phenomenon known as the ‘waiting time paradox.’ The paradox poses a
critical question of whether the findings truly represent the association between time‐to‐
treatment and survival. To arrive at a more robust and inclusive conclusion to aid clinical practice
and improve patients’ outcomes, further research on the effect of extended time‐to‐treatment
on patients’ survival in a broader population and including various treatment modalities is vital.

2.2 Adherence to Treatment Guidelines in Lung Cancer
Providing evidence‐based treatments, as represented by clinical practice guidelines, is one of the
keys to improving quality of cancer care. However, the implementation of clinical guidelines can
be challenging due to various factors, such as patient preference and contraindications. Especially
in a highly aggressive disease like SCLC, therapeutic nihilism – the perception that treatments may
not be useful – might also affect physicians’ recommendation or patients’ decisions about the
treatment. Many studies have described treatment patterns in various cancer patients, including
SCLC,74 but fewer have examined the extent to which patients receive care that adheres to the
clinical practice guidelines.75,76 One US study demonstrated an increasing use of radiation and
chemotherapy in patients diagnosed with limited stage SCLC between 1992 and 2007.74 Another
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study among patients of 65‐years‐old or older reported low, but increasing, use of chemotherapy
in SCLC patients between 1985 and 2005.28 Those two studies did not address the gap in the
literature about the level to which existing guidelines for treatment of SCLC patients have been
adopted, and its trend over time. Furthermore, since clinical guidelines are commonly developed
based on randomized controlled trials, the impact of guidelines adherence in a real‐world setting
remains a subject for investigation. Although evidence‐based treatment should, intuitively, lead
to better survival, empiric data are needed to promote the adoption of clinical guidelines to
improve patients’ outcomes.

2.3 Lung Cancer in Never‐Smokers (LCINS)
An estimated 1 in 4 lung cancer patients worldwide, or 10% in the US, do not have a history of
active tobacco smoking.6 Previous studies have indicated variation in the epidemiology of LCINS
by regions (Asian vs. Western countries), which might have been affected by differences in the
major risk factors.13,57 Findings have been inconclusive, for instance, about whether the risk of
developing LCINS is higher among female than male, or whether never‐smokers with lung cancer
are diagnosed at a younger age than their ever‐smoker counterparts. The mortality rate from
LCINS is relatively high, surpassing those of several other cancers, such as myeloma and brain
cancers.58 However, whether or not the survival of never‐smokers with lung cancer is different
from ever‐smokers remains inconclusive.
The major challenge of studies in LCINS is the limited registries that provide information on
smoking status. The majority of the studies in LCINS have been single‐center hospital‐based with
a relatively small number of sample, which might limit their power to detect small effect sizes.
The Veterans Affairs Health System offers an opportunity to analyze a relatively large number of

23
patients with information on smoking status, through their Veterans Affairs Central Cancer
Registry (VACCR). The registry will also allow us to study a population that is unique from the
general population. Veterans are known to have had a higher risk of lung cancer exposures other
than active tobacco smoking, and they may also have other distinct characteristics that could
affect their survival.
Gaps identified in the three above areas have led to the development of this dissertation. We
expect the results of this dissertation to contribute to an improved understanding of the
prognostic factors of lung cancer.

3. SPECIFIC AIMS
Although lung cancer mortality in the US has declined over the last two decades, lung cancer
continues to affect a significant number of people, and less than 20% of patients survive for at
least 5 years.3 Ensuring early diagnosis and quality continuum of care are key to improving patient
survival. This dissertation focuses on factors associated with survival of lung cancer patients. We
investigated two modifiable factors within the realm of cancer treatment: timeliness of care and
adherence to treatment guidelines; and never‐smoking status. For the latter, the focus of our
dissertation was the never‐smoker veteran population.
The overall goal of this dissertation was to improve our understanding of the provision of
treatment in lung cancer patients and its impact on patients’ overall survival, as well as the
epidemiology of lung cancer in the never‐smoker patients and their survival. The dissertation is
composed of three studies, which are presented in detail in Chapters II–IV. To achieve the
objectives, this dissertation pursued the following specific aims:
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Study 1: To examine the effect of extended time‐to‐treatment on the survival of non‐small cell
lung cancer (NSCLC) patients.
Hypothesis: Treatment started more than four weeks after diagnosis (beyond the commonly
recommended guidelines) increases the risk of mortality.
Study 2: To examine the effect of non‐adherence to treatment guidelines on the survival of small
cell lung cancer (SCLC) patients.
Hypothesis: Non‐adherence to treatment guidelines increases the risk of mortality.
Study 3: To analyze survival of never‐smokers with lung cancer in the VA Health Care System.
Hypothesis: Never‐smokers with lung cancer have better survival than ever‐smokers.

4. CONCEPTUAL FRAMEWORK
We prepared a conceptual model framework to guide this dissertation in identifying study
variables, developing the research design, and interpreting study findings. The framework helped
us to put into perspective the pathway in which each of the prognostic factors affects patients’
survival and how some of those factors are interrelated. We adapted the conceptual model
developed by Carpenter et al. (2012), which was originally used to measure cancer comparative
effectiveness research data needs. The Carpenter’s model was developed through semi‐
structured discussions with 76 clinicians and comparative effectiveness researchers affiliated with
the Agency for Healthcare Research and Quality.77
Patient outcome (e.g., survival) is a result of multiple factors that play a role throughout the
illness trajectory that includes diagnosis and treatment. After cancer diagnosis, most patients go
through a so‐called diagnosis‐to‐treatment interval before treatment is initiated. Patient‐level,
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healthcare provider‐level, and environment‐level factors drive the decisions about the timing of
treatment initiation and the type of treatment, subsequently affecting patients’ survival. Patient‐
level factors include patients’ characteristics and clinical conditions, behavior, and cancer
characteristics. We modified the Carpenter’s model by adding patient preference as we consider
patient preference, in interaction with provider‐level factors, plays an important role in treatment
decision making. We also differentiate between health facility and clinician factors to clearly
illustrate factors that influence adherence to guidelines and treatment decision in each health
facility and clinician level. Given that this dissertation is a retrospective secondary data analysis,
we were unable to investigate some of the prognostic factors (as indicated by the dashed lines or
the italic texts in Figure 4).

26

Figure 4. Conceptual framework of factors affecting the survival of lung cancer patients
Diagnosis‐to‐treatment interval
Diagnostic
- Modality of
assessment
- Time

Cancer Characteristics
- Tumor stage
- Tumor grade
- Histology
- Molecular profile

Treatment
- Type (adherence to
guidelines)
- Timeliness
- Intent (curative,
supportive)
- Sequence
- Completeness

Intermediate
Outcomes
- Tumor response
- Disease progression
- Recurrence
- Toxicities
- Physical and mental
well‐being

Patient preference

Environmental factors
- Environmental exposures
- Health resources
- Social supports
- Stigma

Patient Characteristics
- Age
- Gender
- Family history
- Race/ethnicity
- Geography
- Insurance status
- Socioeconomic status
- Health literacy
- Genetic
Clinical conditions
- Comorbidity
- Symptoms
- Performance status

Patient Behavior
- Smoking
- Alcohol use
- Physical activities
- Diet

Health Facility Factors
- Guidelines adoption
- Care system and
coordination

Clinician Factors
- Experience
- Perception of prognosis
- Agreement with treatment
guidelines
- Communication style

* Modified from the proposed new model of measures for patient‐centered cancer outcomes research (Carpenter et al., 2012).
** Predictors in dashed‐line boxes and factors in italic are not studied in this dissertation; boxes with the blue line are the central of this dissertation.

Survival
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5. METHODOLOGY
To achieve the aims of the dissertation, we conducted three studies of secondary data with a
retrospective cohort design. We utilized two nationwide hospital‐based databases: the National
Cancer Data Base and the Veterans Affairs Central Cancer Registry. Overall 5‐year survival was
used as the primary outcome of all three studies. We also analyzed predictors for extended time‐
to‐treatment and non‐adherence to treatment guidelines. In our first study, we used the term
‘extended time‐to‐treatment’ to represent treatment initiated more than 4 weeks after diagnosis,
or what in other studies is referred as treatment delay. The multivariable analyses were done
using Cox regression and logistic regression. Detailed descriptions of the methods used to address
each study aim are given in Chapters II–IV.

5.1 National Cancer Data Base
The National Cancer Data Base (NCDB) is a clinical oncology database sourced from hospital
registry data collected by more than 1,500 Commission on Cancer (CoC)‐accredited facilities. The
database is jointly sponsored by the American College of Surgeons and the American Cancer
Society. The database represents approximately 70% of newly diagnosed cancer cases in the US.78
Hospitals accredited by the CoC are required to abstract and follow all cancer cases diagnosed
and/or initially treated at the corresponding hospital. The National Cancer Data Base applies the
reporting standard similar to state health departments and federal cancer registry data systems,
including the SEER program and the National Program of Cancer Registries.78 Given the fact that
the database only covers cases reported by CoC‐accredited facilities, the data might not be
representative of all hospitals across the US.79 Nevertheless, in addition to its wide coverage, the
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NCDB offers a valuable opportunity to analyze more in‐depth clinical information that is not
present in most cancer registries, such as comorbidity score, time‐to‐treatment, and
chemotherapy status.

5.2 Veterans Affairs Central Cancer Registry
By design, the Veterans Affairs Central Cancer Registry (VACCR) consists information on cancer
diagnosis and treatment submitted by local cancer registry staff at each of the 132 Veterans
Affairs Medical Centers (VAMCs), which diagnose and/or treat veterans with cancer.80 The VACCR
is unique, as the database offers the opportunity to study cancers in never‐smokers, which is not
feasible using other cancer registries due to the absence of smoking status information.
The database only consists of the veteran population who are eligible to receive VA health
care benefits. The Department of Veterans Affairs estimated that there are 5.6 million
beneficiaries out of 22.3 million veterans.81 The basic eligibility criteria for military members to
qualify for VA health care benefits includes, but is not limited to, the following:82


Individuals who served in active military service and were separated under any condition
other than dishonorable discharge.



Current and former members of the Reserves or National Guard who were called to active
duty by a federal order and completed the full period for which they were called or
ordered to active duty.



Family members of Veterans ‐ under certain circumstances, family members of Veterans
are eligible for health benefits, such as the spouse or widow(er) and the dependent
children of a qualifying sponsor who died of a service‐connected disability, etc.
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CHAPTER II: IMPACT OF TIME‐TO‐TREATMENT ON OVERALL SURVIVAL OF NON‐
SMALL CELL LUNG CANCER PATIENTS ‐ AN ANALYSIS OF THE NATIONAL CANCER
DATABASE
Abstract
Background: The association between time‐to‐treatment and outcomes in lung cancer has not
been conclusively established. In this study, we have evaluated the effect of time‐to‐treatment
on the overall 5‐year survival of non‐small cell lung cancer (NSCLC) patients with different cancer
stages at diagnosis. Methods: We analyzed data of adult patients newly diagnosed with NSCLC in
2003–2011 (N = 693,554) from the National Cancer Data Base (NCDB). Extended Cox regression
with Counting Process was used to model the effect of time‐to‐treatment on survival, adjusted
for demographic and clinical factors. The multivariable analyses were performed separately for
the different stage at diagnosis groups. Time‐to‐treatment was defined as the interval between
diagnosis and treatment initiation, with the categories of (i) 0 day, (ii) 1 day–4 weeks, (iii) 4.1–6.0
weeks, and (iv) > 6 weeks (the 1 day–4 weeks group was considered the reference group). Results:
We found that, compared to treatment initiated between 1 day and 4 weeks after diagnosis, time‐
to‐treatment 4.1–6.0 weeks was associated with a lower risk of death among patients with early‐
stage cancer (aHR, 0.84 [95% CI, 0.82‐0.85]), with locally advanced cancer (aHR, 0.82 [95% CI,
0.80‐0.83]), and with metastatic cancer (aHR, 0.75 [95% CI, 0.74‐0.76]). Similarly, a lower risk of
death was also associated with time‐to‐treatment longer than 6 weeks in patients with any cancer
stage at diagnosis. However, a subset analysis among early‐stage patients who received surgery
only showed that extended time‐to‐surgery was associated a higher risk of death (aHR 4.1‐6.0 weeks,
1.06 [95% CI, 1.03–1.09]; aHR>6 weeks 1.17 [95% CI, 1.14–1.20]). Conclusion: Our findings highlight
that although time‐to‐treatment should not be compromised, it is imperative to ensure that
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patients receive optimal pre‐treatment assessments rather than rushing the treatment. Future
research should focus on examining clinical characteristics to determine an optimal time‐to‐
treatment to achieve best possible survival for NSCLC patients.

Introduction
Lung cancer is the leading cause of cancer deaths in the United States (US) and worldwide.1 The
1‐ and 5‐year overall survival rates of lung cancer patients (47% and 18%, respectively) are lower
than those of other common cancers.3 Therefore, much research has been conducted to improve
our understanding regarding the multiple factors that affect the survival of lung cancer patients.
In general, timely care has been shown to positively affect patients’ survival. Timeliness of
care is defined as the system’s capacity to provide care quickly after a need is recognized.83
Delayed initiation of treatment could increase psychological distress and affect disease prognosis
among cancer patients.35,37 A large population‐based study in the US reported that 36.7% of lung
cancer patients experienced treatment delay (diagnosis‐to‐treatment interval of >35 days).73 Age,
race, stage at diagnosis, comorbidity, and type of hospital have also been associated with
treatment delay.43,44
Despite the important effect of time‐to‐treatment on patients’ outcomes, previous studies in
lung cancer have been inconclusive. A study of non‐small cell lung cancer (NSCLC) patients aged
66 years old and older showed an adverse effect of prolonged time‐to‐treatment on survival.44 An
adverse effect of extended time‐to‐treatment was also found in two other studies of early‐stage
NSCLC patients who had surgery.45,73 On the other hand, several studies reported that longer time‐
to‐treatment was associated with improved survival.41,46,49 This association is often referred as the
‘waiting time paradox’ and has also been observed in other cancers, such as colorectal and
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endometrial cancer.84 A possible reason for this paradox is that patients with more severe
conditions tend to receive treatment right away, but despite the immediate treatment, their
severe condition still leads to poor outcomes. The inconsistent results of studies on time‐to‐
treatment might also be related to the variation in the definition and cut‐off point used as the
recommendations on time‐to‐treatment of NSCLC also vary.38‐40 For instance, in the United States
(US), a proposed recommendation of treatment initiation for NSCLC other than metastatic cancer
is within 6 weeks of diagnosis, while the general recommendation in the United Kingdom is within
4 weeks after diagnosis.38 In the Netherlands, however, the treatment is recommended to start
within 35 calendar days of the patient’s first visit to a pulmonologist.85
Since timeliness of care is modifiable, evidence pertaining to its effect on survival is of
particular importance.86 The objective of this study was to examine the effect of time‐to‐
treatment on the overall survival of NSCLC patients. We utilized a national hospital‐based dataset
that provided a more representative sample of NSCLC patients in the US than the previous studies.

Methods
We analyzed the National Cancer Data Base (NCDB) for the period 2003–2011. The NCDB is a
national hospital‐based oncology dataset, collected from more than 1 500 Commission on Cancer
accredited facilities. The database is jointly sponsored by the American College of Surgeons and
the American Cancer Society and is estimated to represent nearly 70% of new cancer diagnoses
in the US. 87,88 The NCDB records information about patient demographics, clinical characteristics,
treatment, and outcomes. This study used de‐identified data, and thus, was exempt from the
Institutional Review Board review.
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Study population
Patients aged 18 years and older who were diagnosed with NSCLC from 2003 to 2011 and
underwent any surgery, chemotherapy or radiation at the reporting facilities as their first‐course
treatment were considered eligible for this study.

Outcome and predictors
The primary outcome of this study was 5‐year overall survival (OS) time, defined as the time from
the date of diagnosis to the date of death, or the last contact if the patient was still alive or lost
to follow‐up (the time was censored). The primary predictor was time‐to‐treatment, defined as
the period between diagnosis and initiation of any first‐course treatment. We categorized time‐
to‐treatment based on the commonly recommended time‐to‐treatment and the proposed
recommendation in the US (within the first 4 weeks and 6 weeks after diagnosis, respectively).40
The categories of time‐to‐treatment are: (i) 0 day, (ii) 1 day to 4 weeks, (iii) 4.1–6.0 weeks, and
(iv) > 6 weeks, with 1 day to 4 weeks as the reference group. We distinguished 0 day from the 1
day to 4 weeks on the assumption that patients who received treatment on the same day of
diagnosis might harbor specific conditions different from other patients (e.g., have less severe
symptoms and were thus eligible for prompt tumor removal procedure or require an emergent
procedure). The covariates adjusted in the analysis were the age at diagnosis, sex, race,
urban/rural status, distance to the reporting hospital, primary payer, facility type, stage at
diagnosis, histology, treatment type, and Charlson‐Deyo comorbidity score.89 Detailed
information about how variables in the NCDB are defined by the American College of Surgeons is
provided elsewhere.87
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Statistical analysis
Descriptive statistics were presented as proportions for the categorical variables, and medians
with inter‐quartile range (IQR) for the continuous variables. In the bivariate analysis, a chi‐square
test was used to study the association between each of the patient characteristics and time‐to‐
treatment. The association between each predictor and OS time was examined using a Cox
Proportional Hazards model.
Prior to the analysis, we examined the Proportional Hazards (PH) assumption to determine
whether the hazards ratio (HR) for any pair of levels of predictors other than time‐to‐treatment
was constant over time. Using a graphical approach and Schoenfeld’s test, we identified non‐
proportionality of the HRs for several predictors, including time‐to‐treatment, suggesting that the
hazard rates were not constant over time. We handled this non‐proportionality of HRs differently
for the time‐to‐treatment variable and other predictors. We considered the time‐to‐treatment
variable as having an inherent time‐dependent nature. The risk of death of the patients differed
before and after receiving treatment. Prior to starting treatment, patients have a relatively similar
risk to those who did not receive treatment. The risk changes after they start or completed
treatment. To take into account this time‐dependent risk, we applied the Counting Process
method.90 By this approach, each case was handled as two observations: one from the time of
diagnosis to receiving treatment, and one from starting treatment to either death or loss to follow
up. Other predictors that do not satisfy the PH assumption were handled through Stratified Cox
regression.90 We fitted the Counting Process and Stratified Cox regression in the final analyses.
Multivariable analyses were performed separately for the different stage at diagnosis group,
which were divided into early‐stage (stage I and II), locally advanced (stage III), and metastatic
disease (stage IV). We performed subset analyses for patients considered as having a relatively
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good prognosis (early‐stage patients who received surgery only). For this purpose, we excluded
patients who died within the first month after diagnosis since they are likely to have more severe
clinical conditions than the rest of the patients. The Kaplan‐Meier estimator was used to produce
survival estimates.91 The significance level for the analysis was set at p‐value < 0.05. All statistical
analyses were performed using the statistical software package SAS, version 9.4 (SAS Institute
Inc., Cary, NC).

Results
From 2003 to 2011, the NCDB recorded 1,010,492 patients diagnosed with NSCLC. We excluded
259,425 cases who were not eligible for our study due to, for example, not receiving treatment in
the reporting facilities or having unknown treatment status. Out of 751,067 eligible cases, we
excluded 59,603 (7.9%) largely due to missing information on stage at diagnosis and time‐to‐
treatment (Figure. 5). In total, 691,464 patients were included in the analysis. There were no
substantial differences between the excluded and analyzed cases, except for histology and
comorbidity score. The cases included in the analysis had a higher proportion of adenocarcinoma
(46.4%) and comorbidity scores of either 1 or 2 (39.3%) compared to the excluded cases (37.3%
and 33.8%, respectively). The median follow‐up period was 15 months (IQR = 30).
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Figure 5. Selection of study population
NSCLC diagnosed from 2003 to
2011 (N = 1,010,492)

Excluded cases
Diagnosed at the reporting facility, but all treatment decisions were made
elsewhere (N = 83,183)

N = 927,309
- Did not receive first‐course treatment at the reporting facility (N = 158,245)
- Treatment status was unknown (N = 15,605)
- Only received hormone or immunotherapy (N = 2,392)

Eligible cases (N = 751,067)
- Missing information on stage at diagnosis (N = 40,925)
- Stage at diagnosis was either 0 or occult (N = 1,355)

N = 708,787
- Missing information on time‐to‐treatment (N = 17,264)
- Possible data error on time‐to‐treatment information (N = 55)
- Patients received treatment more than 5 years after diagnosis (N = 4)

Analyzed (N = 691,464)

1. Descriptive analysis of time‐to‐treatment and patients’ characteristics
Overall, 42.6% of patients started treatment more than 4 weeks after diagnosis. The median time‐
to‐treatment was different between patients with metastatic cancer (18 days, [IQR, 11–36]) and
less advanced stages. The median for patients with early stage and locally advanced disease was
28 days (IQR, 2–51) and 27 days (IQR, 13–46), respectively.
Patients’ demographic and clinical characteristics are presented in Table 5. Time‐to‐treatment
was significantly associated with all patient demographic and clinical characteristics analyzed in
this study (please see the note under Table 5). The proportion of patients receiving treatment
within the first 4 weeks of diagnosis appears to be higher among those who were younger than
65 years, of high income, had private insurance, diagnosed with early‐stage or had surgery.
Patients with Medicare (mostly age ≥ 65 years) tended to start treatment more than 6 weeks after
diagnosis. The median OS time was 54 months (IQR = 95) for early stage, 15 months (IQR = 29.2)
for a locally advanced stage, and 6.4 months (IQR = 11.3) for patients with metastatic cancer.
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Table 5. Patients’ socio‐demographic and clinical characteristics by time‐to‐treatment a
0 days
n (%)
Sex
Male
Female
Age at Diagnosis
<65 year
65‐74 year
75+ year
Racial Group
White
Black
Other
Unknown
Urban/Rural
Metro
Urban
Rural
Unknown
Distance to Hospital
<=10 miles
11‐50 miles
51‐100 miles
>100 miles
Unknown
Primary Payer
Not Insured
Private Insurance
Medicaid
Medicare
Other government
insurance
Unknown
Facility Type
CCP
CCCP
Academic/Research
Program
Other
Stage at Diagnosis
Stage I
Stage II
Stage III
Stage IV
Histology
Adenocarcinoma
Large‐cell
Squamous cell
Adenosquamous
NSCLC, NOS
Others

1 day ‐ 4 weeks
n (%)

4.1‐6 weeks
n (%)

> 6 weeks
n (%)

Total
n (%)

49,251 (48.9)
51,536 (51.1)

164,691 (55.7)
131,060 (44.3)

62,251 (54.1)
52,841 (45.9)

94,263 (52.4)
85,571 (47.6)

370,456 (53.6)
321,008 (46.4)

39,355 (39.1)
37,243 (37.0)
24,189 (24.0)

125,625 (42.5)
97,484 (33.0)
72,642 (24.6)

41,071 (35.7)
40,641 (35.3)
33,380 (29.0)

57,733 (32.1)
63,675 (35.4)
58,426 (32.5)

263,784 (38.2)
239,043 (34.6)
188,637 (27.3)

89,131 (88.4)
8,591 (8.5)
2,216 (2.2)
849 (0.8)

255,578 (86.4)
30,661 (10.4)
7,297 (2.5)
2,215 (0.8)

100,561 (87.4)
11,000 (9.6)
2,628 (2.3)
903 (0.8)

151,589 (84.3)
22,354 (12.4)
4,511 (2.5)
1,380 (0.8)

596,859 (86.3)
72,606 (10.5)
16,652 (2.4)
5,347 (0.8)

80,011 (79.4)
14,332 (14.2)
1,867 (1.9)
4,577 (4.5)

227,819 (77.0)
47,290 (16.0)
6,952 (2.4)
13,690 (4.6)

88,734 (77.1)
18,613 (16.2)
2,560 (2.2)
5,185 (4.5)

141,738 (78.8)
26,752 (14.9)
3,427 (1.9)
7,917 (4.4)

538,302 (77.9)
106,987 (15.5)
14,806 (2.1)
31,369 (4.5)

48,695 (48.3)
38,043 (37.8)
7,268 (7.2)
3,947 (3.9)
2,834 (2.8)

155,000 (52.4)
105,671(35.7)
16,630 (5.6)
9,109 (3.1)
9,341 (3.2)

59,042 (51.3)
42,296 (36.8)
6,591 (5.7)
3,817 (3.3)
3,346 (2.9)

93,773 (52.2)
63,715 (35.4)
10,820 (6.0)
6,455 (3.6)
5,071 (2.8)

35,651 (51.6)
249,725 (36.1)
41,309 (6.0)
23,328 (3.4)
20,592 (2.9)

2,127 (2.1)
34,327 (34.1)
4,318 (4.3)
56,907 (56.5)

11,524 (3.9)
96,985 (32.8)
17,905 (6.1)
159,124 (53.8)

2,843 (2.5)
34,205 (29.7)
5,717 (5.0)
68,263 (59.3)

4,642 (2.6)
45,406 (25.3)
10,657 (5.9)
111,653 (62.1)

21,136 (3.1)
210,923 (30.5)
38,597 (5.6)
395,947 (57.3)

1,025 (1.0)

3,539 (1.2)

1,464 (1.3)

2,871 (1.6)

8,899 (1.3)

2,083 (2.1)

6,674 (2.3)

2,600 (2.3)

4,605 (2.6)

15,962 (2.3)

8,828 (8.8)
54,302 (53.9)

34,131 (11.5)
174,009 (58.8)

12,951 (11.3)
64,497 (56.0)

18,899 (10.5)
93,999 (52.3)

74,809 (10.8)
386,807 (55.9)

37,357 (37.1)

87,141 (29.5)

37,510 (32.6)

66,760 (37.1)

228,768 (33.1)

300 (0.3)

470 (0.2)

134 (0.1)

176 (0.1)

1,080 (0.2)

58,140 (57.7)
9,998 (9.9)
15,580 (15.5)
17,069 (16.9)

52,336 (17.7)
20,247 (6.9)
73,597 (24.9)
149,571 (50.6)

34,514 (30.0)
11,866 (10.3)
32,801 (28.5)
35,911 (31.2)

69,743 (38.8)
20,401 (11.3)
47,672 (26.5)
42,018 (23.4)

214,733 (31.1)
62,512 (9.0)
169,650 (24.5)
244,569 (35.4)

57,537 (57.1)
4,015 (4.0)
22,773 (22.6)
2,259 (2.2)
8,794 (8.7)
5,409 (5.4)

130,411 (44.1)
12,455 (4.2)
76,202 (25.8)
4,099 (1.4)
63,364 (21.4)
9,220 (3.1)

51,939 (45.1)
4,015 (3.5)
34,268 (29.8)
1,872 (1.6)
19,875 (17.3)
3,123 (2.7)

80,613 (44.8)
5,477 (3.1)
55,784 (31.0)
2,980 (1.7)
29,740 (16.5)
5,240 (2.9)

320,500 (46.4)
25,962 (3.8)
189,027 (27.3)
11,210 (1.6)
121,773 (17.6)
22,992 (3.3)
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Table 5. (cont’d)
0 days
n (%)
Charlson/Deyo
Comorbidity Score
0
1
2
Treatment received
Surgery only
Radiation only
Chemotherapy only
Chemoradiation
Surgery + chemo
and/or radiation
Unknown/others

1 day ‐ 4 weeks
n (%)

4.1‐6 weeks
n (%)

> 6 weeks
n (%)

Total
n (%)

56,523 (56.1)
32,673 (32.4)
11,591 (11.5)

184,555 (62.4)
80,266 (27.1)
30,930 (10.5)

71,285 (61.9)
31,819 (27.7)
11,988 (10.4)

107,284 (59.7)
50,920 (28.3)
21,630 (12.0)

419,647 (60.7)
195,678 (28.3)
76,139 (11.0)

62,359 (61.9)
4,556 (4.5)
3,909 (3.9)
9,379 (9.3)

45,206 (15.3)
64,785 (21.9)
51,526 (17.4)
102,717 (34.7)

28,223 (24.5)
17,861 (15.5)
19,852 (17.3)
33,225 (28.9)

52,532 (29.2)
36,697 (20.4)
26,783 (14.9)
41,198 (22.9)

188,320 (27.2)
123,899 (17.9)
102,070 (14.8)
186,519 (27.0)

19,728 (19.6)

28,389 (9.6)

15,104 (13.1)

21,502 (12.0)

84,723 (12.3)

856 (0.9)

3,128 (1.1)

827 (0.7)

1,122 (0.6)

5,933 (0.9)

Abbreviations: CCP, Community Cancer Program; CCCP, Comprehensive Community Cancer Program; NSCLC, Non‐Small Cell Lung
Cancer; NOS, Not Otherwise Specified; IQR, Inter‐quartile Range.
a
The chi‐square test for all comparisons resulted in a p‐value < 0.001.

2. The effect of time‐to‐treatment on overall survival
The multivariable analyses showed different effects of time‐to‐treatment on overall survival
between patients with an early and advanced stage of diseases.

2.1. Early‐stage disease: The multivariable analysis (Table 6) showed a lower risk of death in
patients who received treatment at the same day of diagnosis, compared to those who initiated
treatment between 1 day and 4 weeks after diagnosis (adjusted HR [aHR] = 0.84 [95% CI, 0.82–
0.85]). Similarly, lower risk of death was also associated with time‐to‐treatment longer than 4
weeks (aHR, 0.93 [95% CI, 0.91–0.95]) and longer than 6 weeks of diagnosis (aHR, 0.92 [95% CI,
0.91–0.94]) (Table 6). However, a subset analysis among patients who received surgery only,
showed that surgery between 4 and 6 weeks was associated with a 6% increased risk of death
(aHR, 1.06 [95% CI, 1.03–1.09]). A higher risk of death (17%) was detected among early‐stage
patients who received surgery more than 6 weeks after diagnosis (aHR, 1.17 [95% CI, 1.14–1.20])
(Table 7).
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2.2. Locally‐advanced stage: Compared to treatment initiated 1 day to 4 weeks after diagnosis,
either shorter or longer time‐to‐treatment was associated with a lower risk of death (aHR0 day 0.73
[95% CI, 0.71–0.74]; aHR 4.1‐6.0 weeks 0.82 [95% CI, 0.80–0.83]; aHR>6 weeks 0.71 [95% CI, 0.70–0.72]).

2.3. Metastatic cancer: Similar to findings in patients with locally advanced disease, we observed
a lower risk of death among patients who received treatment at the same day of diagnosis or after
4 weeks (aHR0 day 0.75 [95% CI, 0.73–0.76]; aHR 4.1‐6.0 weeks 0.75 [95% CI, 0.73–0.76]; aHR>6 weeks 0.58
[95% CI, 0.57–0.59]).

Table 6. Adjusted Hazard Ratios (aHR [95% CI]) for 5‐year mortality associated with time‐to‐
treatment*
Time‐to‐Treatment

Early stage
(N = 277,245)

0 day

0.84 (0.82–0.85)

Locally advanced
disease
(N = 169,650)
0.73 (0.71–0.74)

1 day to 4 weeks
4.1‐6.0 weeks
>6 weeks

Ref.
0.93 (0.91–0.95)
0.92 (0.91–0.94)

Ref.
0.82 (0.80–0.83)
0.71 (0.70–0.72)

Metastatic disease
(N = 244,569)

Ref.
0.75 (0.74–0.76)
0.58 (0.57–0.59)

0.75 (0.74–0.76)

Abbreviations: CI, Confidence Interval.
*Model was adjusted for age, sex, race, urban/rural, distance to hospital, facility type, primary payer, Charlson/Deyo
comorbidity score, histologic type, and treatment modalities.

Table 7. Adjusted Hazard Ratios (aHR [95% CI]) for 5‐year mortality, associated with time‐to‐
treatment in early‐stage patients who received surgery only*
aHR [95% CI]
0 day

0.91 (0.89‐0.93)

1 day to 4 weeks
4.1‐6.0 weeks
>6 weeks

Ref.
1.06 (1.03‐1.09)
1.17 (1.14‐1.20)

*Model was adjusted for age, sex, race, urban/rural, distance to hospital, facility type, primary payer, Charlson/Deyo
comorbidity score, and histologic type.

39
Excluded patients who died within 1 month after diagnosis.

Discussion
The Institute of Medicine has established timeliness of care as one of the dimensions of healthcare
quality.92,93 However, delay in receiving treatment remains a problem in a fairly significant
proportion of cancer patients.43,44 Although the present study was not able to prove the
hypothesis of adverse effects of extended time‐to‐treatment on the OS of overall NSCLC patients,
we showed that extended time‐to‐treatment is an independent predictor of mortality among
early‐stage patients who receive surgery.
Our findings indicate a complex association between time‐to‐treatment and survival.
Contrary to our hypothesis, time‐to‐treatment longer than four weeks was significantly associated
with a lower risk of death among patients of all cancer stage. In early‐stage patients, however,
the difference in risk of death by time‐to‐treatment is subtle compared to patients with locally
advanced or metastatic cancers. However, a subset analysis among early‐stage patients who
received surgery alone, who were considered as having a better prognosis than the rest of the
groups, showed an association of the opposite direction. Compared to treatment initiated within
1 day to 4 weeks, a longer time‐to‐treatment among these patients was associated with a
decreased 5‐year survival. Although the increased risk was modest among those who received
treatment within 1 day to 4 weeks, the risk was amplified among patients who were treated more
than 6 weeks after diagnosis, providing strong evidence of the effect of time‐to‐treatment.
Our findings were generally inconsistent with previous study findings. One study among US
veterans showed an increased risk of death associated with greater timely care (aHR, 1.6 [95% CI,
1.3‐1.9]), independent of type of treatment.94 Another study among Medicare beneficiaries
reported varying results, of which an improved OS was associated with a diagnosis‐to‐treatment
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interval of 35 days in localized disease (aHR, 0.86 [95% CI, 0.80–0.91]) and among patients with
distant disease who survived ≥ 1 year (aHR, 0.86 [95% CI, 0.74–0.99]), but was associated with a
decreased OS for patients who survived < 1 year.44 Nevertheless, our findings in early‐stage
patients who received surgery were consistent with results reported in two previous studies. A
study using NCDB data among patients with stage I NSCLC, but with a different analytical
approach, found that each week of delay of surgery increased the hazard of death by 0.4% (aHR,
1.004 [95% CI, 1.002–1.007]).45 Another study on delay in surgery among patients diagnosed at a
community center suggested a similar association but was not statistically significant (aHR, 1.04
[95% CI, 1.00–1.09]).73
Similar to our overall analysis, counter‐intuitive results that extended time‐to‐treatment are
associated with longer survival have been reported by multiple studies in the US and other
countries, not limited to lung cancer.47,84 This phenomenon is commonly referred as the ‘waiting
time paradox.’95 The premise behind the waiting time paradox is that the association between
time‐to‐treatment and OS is likely affected by the disease severity at presentation. Patients who
were treated early might have severe symptoms, and inherently have a worse prognosis
compared to patients treated with longer time‐to‐treatment. Another possible reason for the
finding is that among patients with shorter time‐to‐treatment, the treatment plan might involve
a less comprehensive evaluation that puts patients at risk for a worse prognosis.
Our stratification analysis by disease stage failed to distinguish patients’ severity level that
affects both time‐to‐treatment and survival, suggesting a mix of patients' risk within the same
stage. Among early‐stage patients who received surgery, however, the patient population was
likely more homogenous with respect to their clinical conditions. Therefore, the subset analysis
among this population was able to show the adverse effect of extended time‐to‐treatment.
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The adverse effect of extended time‐to‐treatment on OS can be explained by disease
progression. A prolonged waiting period might cause some patients to become ineligible for
curative‐intent therapy, thus reducing their chance of cure. This premise has been shown in
multiple studies of radiotherapy.35,96 A prospective study of 29 lung cancer patients waiting for
radical radiotherapy showed that 21% of potentially curable patients became incurable, and the
cross‐sectional tumor size increased more than three times over the waiting period.35
The strengths of the present study are mainly related to the wide coverage of the database
and the large sample size. The sample size allowed us to perform stratification analyses, without
being underpowered. Furthermore, the database enabled us to account for various potential
confounders. In a study of colorectal cancer, control for more comprehensive confounders led to
a different interpretation of the effect of time‐to‐treatment on OS.47 Our analysis included
patients with multiple primary cancers, who are commonly excluded from analyses using cancer
registry data.97 This inclusion might lead to a higher risk of death in our study cohort. However, a
subset analysis of patients with single primary cancer yielded similar results (data not shown), as
was also found in other studies.97,98
Our results were also subject to several limitations. The CoC‐approved hospitals included in
the NCDB are typically larger, located in urban locations, and provide a higher degree of oncology‐
related specialization, compared to non‐CoC‐approved hospitals.79 Thus, the data might not
represent all hospitals in the US. The influence of unmeasured confounders, particularly those
that may affect the decision to either expedite or postpone treatment (e.g., tumor aggressiveness,
performance status), was likely the reason for the counter‐intuitive findings among locally
advanced and metastatic NSCLC.
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Our results did not lead us to conclude that longer time‐to‐treatment leads to better survival.
Instead, we believe that longer time‐to‐treatment does not seem to have detrimental effects for
patients, especially those with a more advanced disease stage. Therefore, ensuring
comprehensive examination and preparation will benefit patients more, rather than rushing the
treatment. However, in patients with operable cancer, it is critically important not to delay
treatment. Future research should focus on identifying patients’ clinical characteristics that could
significantly predict the tolerable time‐to‐treatment to achieve better outcomes, which would be
beneficial for patients and provide a solid basis for improving clinical standards. Such research
would also be particularly relevant given the fact that guidelines for timing of treatment initiation
of NSCLC vary.

Conclusions
This study supports the idea that allocating time for optimal pre‐treatment assessments, although
leading to a longer time‐to‐treatment interval, is likely to benefit patients’ survival. However, it
seems prudent for treatment to start within 4 weeks of diagnosis in patients with resectable early‐
stage lung cancer. This finding is relevant to the expected increased identification of early‐stage
patients following improvements in screening programs and recent recommendations from the
US Preventive Services Task Force. Despite the multiple factors that lead to treatment delay, every
attempt must be made to decrease treatment delays caused by system‐based factors.
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CHAPTER III: ADHERENCE TO TREATMENT GUIDELINES IN PATIENTS WITH
SMALL CELL LUNG CANCER ‐ PREDICTORS AND IMPACT ON PATIENTS’ SURVIVAL
Abstract
Background: Small cell lung cancer (SCLC) is a lethal disease with just a 6.5% of 5‐year survival
rate. Treatment for SCLC has not changed much over the past three recent decades, but data on
the level of adherence to treatment guidelines and its effect on survival are lacking. Methods: We
conducted secondary data analyses of patients newly diagnosed with SCLC in 1998—2012 who
were recorded in the National Cancer Data Base. Adherence was assessed based on the National
Comprehensive Cancer Network Guidelines. Multilevel logistic regressions were used to analyze
predictors of non‐adherence to treatment guidelines. Cox Frailty regressions were used to
examine the effect of guidelines adherence on patients’ 5‐year overall survival. Data were
analyzed separately for limited stage (LS) and extensive stage (ES) SCLCs. Results: Our study found
that patients who did not receive guideline‐recommended treatment were more likely to be
older, black, have a high comorbidity burden, and be uninsured or beneficiaries of
Medicare/Medicaid. Patients diagnosed/treated in cancer centers in the South and West regions
were more likely not to receive guideline‐recommended treatment, compared to patients in the
Northeast region. After controlling for other covariates, receiving inadequate treatment (not
adhere to the guidelines) was associated with higher risk of death in patients with LS‐SCLC (aHR,
1.93 [95% CI, 1.88–1.98]) and ES‐SCLC (aHR, 2.02 [95% CI, 1.97–2.07]). Conclusion: This study
provides evidence of the strong survival benefit of receiving guidelines‐recommended treatment.
Further research is needed to identify patient and provider‐level factors that could preclude
patients from receiving guidelines‐recommended treatment.
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Introduction
Small cell lung cancer (SCLC) is a very aggressive sub‐type of lung cancer, with rapid growth and
metastasis.27 This disease represents about 13% of all lung cancer cases in the United States (US),
which translates into nearly 30,000 patients diagnosed with SCLC every year.2,99 The overall 5‐year
survival rate of SCLC patients is approximately 6.5%.3 More than half of the patients are diagnosed
at an extensive stage with extensive metastases, of whom less than 5% survive two years after
diagnosis.99
Treatment for SCLC has not changed much in the last 30 years. Chemotherapy has been the
cornerstone of treatment for all stages, while a combination of chemotherapy and radiotherapy
is recommended for patients with a limited stage of the disease.27 Recent data suggest that
patients with limited stage SCLC might benefit from surgery.26 In general, initial responses to
treatment of SCLC are extremely high.27 Although the majority of patients experience relapse
within two years, treatment with chemotherapy and radiotherapy leads to rapid relief of
symptoms and improves survival. 27,100
Despite the known benefits of the treatments, some SCLC patients might not receive
guideline‐recommended treatments.101 Most patients with SCLC have a history of heavy smoking,
which leads to the development of other comorbid conditions that often preclude SCLC patients
from receiving stage‐appropriate treatment.28 Considering the low survival rate and that without
treatment patients have a 2.5‐times greater risk of death,101 prompt treatment decisions are
essential to facilitate optimal outcomes. For many patients and their families, making a decision
about treatment that has uncertain outcomes along with potential side effects is very difficult,
especially when combined with the life‐changing news of a cancer diagnosis with a poor
prognosis. Some patients may choose not to undergo aggressive treatment of any kind, regardless
of whether or not they are recommended by experts in the field following consensus guidelines.
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A study among elderly patients with SCLC indicated low, but increasing, use of
chemotherapy.28 Using a National Cancer Data Base (NCDB), Gaspar et al. (2012) reported the
treatment pattern in SCLC patients diagnosed between 1992 and 2007.74 However, to what extent
the treatment has been provided with respect to existing guidelines for SCLC treatment and
predictors of guidelines non‐adherence remain unclear. This information is important to help
identify barriers to receiving guideline‐recommended treatment to improve quality of care. To
address this gap, we analyzed more recent NCDB data to analyze the trend and factors associated
with adherence to SCLC clinical guidelines and examined the impact of guidelines adherence on
patients’ survival.

Methods
We analyzed a retrospective longitudinal data from the National Cancer Data Base (NCDB), a
hospital‐based oncology dataset collected from more than 1,500 Commission on Cancer
accredited facilities nationwide. The database is jointly sponsored by the American College of
Surgeons and the American Cancer Society. The NCDB represents nearly 70% of new cancer
diagnoses in the US.88 The data source for this study is a de‐identified database, and thus, was
exempt from the Institutional Review Board review.

Study population
The study population was composed of patients aged 18 years or older, newly diagnosed with
primary SCLC between 1998 and 2012. Our analysis included only patients who received their
first‐course treatment at the reporting facility. We excluded cases with the following conditions
from the analysis: without information on stage at diagnosis, incomplete information about
treatment status, did not receive treatment due to either contraindication or died prior to
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planned treatment. Patients diagnosed with stage I, II or III were classified as a limited stage, and
patients with metastatic cancer or stage IV were classified as an extensive stage. Our data covered
a follow‐up period of patient’s status until 2012, with a median follow‐up time of 8.5 months (IQR
= 13.2).

The primary outcome of interest
In this study, we utilized the National Comprehensive Cancer Network (NCCN) Guidelines to
define ‘adherence’ and ‘adequate’ treatment.(National Comprehensive Cancer Network, 2016)
For the limited stage of disease (LS‐SCLC), treatment was considered as ‘adequate’ or ‘adhered to
the guidelines,’ if the patients received either chemo‐radiation or surgery plus chemotherapy;
irrespective of the treatment sequence. Treatment of patients with extensive stage disease (ES‐
SCLC) was deemed ‘adequate’ or ‘adhered to the guidelines,’ if they received multiple
chemotherapy agents. To evaluate the impact of adherence to treatment guidelines, we analyzed
patients’ 5‐year overall survival as the outcome, which was defined as the time from the date of
diagnosis to the date of death (from all causes) or the date of the last contact of record in the
dataset.
We included data from the period of 1998–2012 to analyze the trend of treatment provision,
but we only included cases diagnosed from 2003 onwards to analyze factors associated with non‐
adherence and its impact on patients’ survival. This approach was taken because data on
comorbidity, which is an important factor affecting treatment planning and survival, were not
collected prior to 2003. For survival analysis, we did not include cases diagnosed in 2012 as these
cases do not have follow‐up information.
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Statistical analysis
Descriptive statistics are presented as proportions for the categorical variables, and medians with
inter‐quartile ranges for the continuous variables. In the bivariate analysis, a chi‐square test or
Wilcoxon test was used, as appropriate, to examine the association between each of the
predictors and adherence to treatment guidelines.
In the multivariable analysis, we applied multilevel regressions with hospital as the random
effect to adjust for the clustering effect or potential dependence among patients
diagnosed/treated from the same hospital. The multivariable analyses were performed separately
for LS‐SCLC and ES‐SCLC. We included in the multivariable model factors that showed significant
association with the outcome in the univariate analysis. Factors that were included in the analyses
were the age at diagnosis, sex, race, urban/rural status, distance to hospital, primary payer, facility
type, facility region, Charlson‐Deyo comorbidity score, treatment type, and year of diagnosis.
To examine factors associated with adherence to treatment guidelines, we applied multilevel
binary logistic regressions, by excluding patients who did not receive treatment at the reporting
facilities. We tested for interaction terms between age and comorbidity, but the results were not
statistically significant (p = 0.624 in LS‐SCLC; p = 0.073 in ES‐SCLC), and thus no interaction term
included in the model.
The median overall survival (OS) time was estimated using the Kaplan‐Meier estimator. The
primary predictor for the survival analysis was guideline adherence, adjusted for patients’
demographic and clinical factors mentioned above. Prior to the analysis, we examined the
Proportional Hazards (PH) assumption using a graphical approach and Schoenfeld’s test to
determine whether the hazards ratio (HR) for each predictor was constant over time. The
graphical approach suggested no violation to the PH assumption. We applied Cox Frailty
regression (a multilevel form of survival analysis) to examine the effect of guidelines adherence
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on patients’ survival. In the survival analysis, treatment adequacy was categorized into three
categories: (a) adequate treatment, (b) inadequate treatment or (c) no treatment at all. The
purpose of the categorization was to examine in more detail the effect of guidelines adherence
on patients’ survival. The significance level for the analyses was set a priori at p‐value < 0.05. All
statistical analyses were performed using the statistical software package SAS, version 9.4 (SAS
Institute Inc., Cary, NC).

Results
We identified 245,741 patients diagnosed with SCLC since 1998 to 2012. Out of these cases, we
excluded those who were diagnosed at the reporting facility but for whom all treatments or
decisions not to treat were made elsewhere (N = 18,139). Of the 227,602 eligible cases, we
excluded cases with either missing information on stage at diagnosis or occult stage (N = 20,227),
cases who did not receive treatment due to contraindications or died before treatment could be
initiated (N = 5,373), and cases with incomplete information on treatment in which we could not
determine their adherence status (N = 10,331).
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Figure 6. Selection of the study population
First primary SCLC diagnosed from 1998
to 2012
N = 245,741

Excluded cases
Diagnosed at the reporting facility, but all treatment or
decision not to treat was made elsewhere (N = 18,139)

Eligible cases (N = 227,602)
- The stage at diagnosis was either 0 or occult (N = 583)
- Missing information on stage at diagnosis (N =
19,644)
- Did not receive treatment due to contraindications
or patients died prior to planned treatment (N =
5,373)
- Guidelines adherence could not be determined due
to incomplete treatment information (N = 10,331)
Analyzed ‐ descriptive of the trend of
guidelines adherence (N = 191,671)
- Diagnosed prior to 2003 when data on comorbidity
were not collected (N = 64,230)
Analyzed ‐ risk factors associated with
non‐adherence (N = 127,441)
- Diagnosed in 2012 – no follow‐up information (N =
12,640)
Analyzed ‐ survival analysis (N = 114,801)

A total of 191,671 patients were included in the descriptive analysis of the characteristics of
SCLC patients by treatment adequacy (Table 8). Our study population was predominantly white
(90.1%) and resided in either metro or urban areas (92.9%), with a median age at diagnosis of 66
years (IQR = 14). Nearly 62% of the patients used Medicare, Medicaid or other government
insurance. More than half of the patients were diagnosed with an extensive stage of cancer
(59.9%). Nearly 43% of the patients had at least one comorbidity listed in the Charlson‐Deyo
Comorbidity Score.
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Table 8. Characteristics of SCLC patients by treatment received
Patients’
characteristics

Adequate
(N = 130,849)
n
%

Inadequate
(N = 34,623)
n
%

No treatment
(N = 26,199)
n
%

Sex
Male
65,456
50.0
16,992
49.1
12,801
48.9
Female
65,393
50.0
17,631
50.9
13,398
51.1
Age group
< 65
65,114
49.8
11,664
33.7
6,984
26.7
45,357
34.7
12,156
35.1
8,780
33.5
65–74
75+
20,378
15.6
10,803
31.2
10,435
39.8
Median, years (IQR)
65 (± 14)
69 (± 14)
72 (± 15)
Race
White
118,302
90.4
30,710
88.7
23,600
90.1
Black
9,717
7.4
2,987
8.6
1,936
7.4
Others
1,984
1.5
628
1.8
413
1.6
Missing
846
0.7
298
0.9
250
1.0
Urban/rural
Metro
98,072
75.0
26,286
75.9
20,180
77.0
Urban
23,579
18.0
5,869
17.0
4,172
15.9
Rural
3,383
2.6
818
2.4
586
2.2
Missing
5,815
4.4
1,650
4.8
1,261
4.8
Insurance
Not Insured
5,882
4.5
1,373
4.0
1,115
4.3
Private Insurance
46,410
35.5
8,479
24.5
5,095
19.5
Medicaid
9,948
7.6
2,111
6.1
1,444
5.5
Medicare
63,671
48.7
20,968
60.6
17,482
66.7
Other Government
1,702
1.3
441
1.3
221
0.8
Insurance
Missing
3,236
2.5
1,251
3.6
842
3.2
Facility type
Academic/Research
33,947
25.9
9,206
26.6
6,389
24.4
Program
Comprehensive CCP
77,820
59.5
20,183
58.3
15,588
59.5
Community Cancer
18,870
14.4
5,192
15.0
4,191
16.0
Program
Missing
212
0.2
42
0.1
31
0.1
Facility region
Northeast
24,097
18.4
6,506
18.8
4,440
17.0
Midwest
40,524
31.0
9,175
26.5
6,725
25.7
South
51,189
39.1
14,548
42.0
11,240
42.9
West
15,039
11.5
4,394
12.7
3,794
14.5
Stage of SCLC
Limited stage
50,439
38.6
19,373
56.0
7,068
27.0
Extensive stage
80,410
61.5
15,250
44.1
19,131
73.0
Comorbidity score**
0/none
52,638
59.8
11,592
54.3
8,969
49.5
1
25,125
28.6
6,370
29.8
5,655
31.2
2+
10,194
11.6
3,391
15.9
3,480
19.2
*CCP: Community Cancer Program; **Excluded cases diagnosed prior to 2003

Total
(N = 191,671)
n
%
95,249
96,422

49.7
50.3

83,762
43.7
66,293
34.6
41,616
21.7
66 (± 14)
172,612
14,640
3,025
1,394

90.1
7.6
1.6
0.7

144,538
33,620
4,787
8,726

75.4
17.5
2.5
4.6

8,370
59,984
13,503
102,121

4.4
31.3
7.0
53.3

2,364

1.2

5,329

2.8

49,542

25.9

113,591

59.3

28,253

14.7

285

0.2

35,043
56,424
76,977
23,227

18.3
29.4
40.2
12.1

76,880
114,791

40.1
59.9

73,199
37,177
17,065

57.4
29.2
13.4
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Trend of adherence to the treatment guideline
A total of 13.6% of SCLC patients in our study population did not receive treatment in the
reporting facilities. Among those who underwent treatment, 79% received treatment that
adhered to the guidelines. The proportion of adherence to treatment guidelines increased
significantly from 1998 to 2012. The increase, however, was more noticeable in LS‐SCLC (66.4%
to 78.6%; p < 0.001) compared to ES‐SCLC patients (83.1% to 88.5%; p<0.001) (Figure 7). The
majority of LS‐SCLC patients who received inadequate treatment (non‐adhere to the guidelines)
were treated mainly with chemotherapy alone (75.6%). Among ES‐SCLC patients with inadequate
treatment, 65.1% did not receive chemotherapy (mostly received radiation alone) and about 26%
received single‐agent chemotherapy.

Figure 7. Trend of adherence to treatment guidelines in SCLC patients, 1998‐2012*
100
80
60
40
20
0
Limited Stage
(n=69,812)

1998 2000 2002 2004 2006 2008 2010 2012
66.4

68.4

71.0

72.0

73.7

73.4

76.6

78.6

Extensive Stage
83.1
(n=95,660)

83.1

81.3

81.9

84.3

85.2

87.0

88.5

*excluding patients who did not receive treatment at the reporting facilities
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Factors associated with adherence to treatment guidelines
Age, insurance, comorbidity score, facility type, facility region, and year of diagnosis were
independent predictors of guidelines non‐adherence in both LS‐SCLC and ES‐SCLC (Table 9). After
adjusting for other covariates, patients aged 65–74 years had a nearly 50% higher risk to receiving
inadequate treatment compared to patients diagnosed younger than 65 years old (aORLS‐SCLC =
1.40, 95% CI = 1.31–1.50; aORES‐SCLC = 1.37, 95% CI = 1.27–1.46). The risk for receiving inadequate
treatment was even higher among patients diagnosed at 75 years or older (aORLS‐SCLC = 3.24, 95%
CI = 3.00–3.49; aORES‐SCLC = 2.51, 95% CI = 2.33–2.71).
Another strong predictor of guidelines non‐adherence was comorbidity. Compared to having
a comorbidity score of zero, a high comorbidity burden (score of 2 or higher) were associated with
nearly 1.5‐times greater risk of receiving treatment that do not adhere to the guidelines in
patients with LS‐SCLC (aOR, 1.84 [95% CI, 1.71–1.97]) and ES‐SCLC (aOR, 1.30 [95% CI, 1.22–1.40]),
respectively. In both LS‐SCLC and ES‐SCLC, non‐insured patients or those who were covered by
Medicare/Medicaid were more likely to receive inadequate treatment, compared to patients with
private insurance.
We identified regional differences in guidelines non‐adherence. LS‐SCLC patients who were
diagnosed/treated in cancer centers in the South and West regions had about 22‐25% higher odds
to receive inadequate treatment (aORSouth = 1.25 [95% CI, 1.12–1.39]; aORWest = 1.22 [95% CI, 1.07–
1.97]), compared to the Northeast region. Among ES‐SCLC patients, however, we did not find
significant increased risk of guidelines non‐adherence associated with South and West region. On
the contrary, in both stage groups, being diagnosed/treated in facilities in the Midwest was
associated with a reduced risk of guidelines non‐adherence (aORLS‐SCLC = 0.83 [95% CI, 0.70–0.88];
aORES‐SCLC = 0.73[95% CI, 0.65–0.82]), compared to the Northeast region. Our analysis also showed
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that patients diagnosed in more recent years, with either ES‐SCLC or LS‐SCLC, were less likely to
receive inadequate treatment, compared to those who were diagnosed earlier.

Table 9. Adjusted Odds Ratios (aOR [95% CI]) for receiving treatment that did not adhere to
the guidelines among SCLC patients who received treatment at the reporting facilities*

Sex
Female
Male
Age at Diagnosis,
year
<65
65–74
75+
Race
White
Black
Other
Urban/Rural**
Metro
Urban
Rural
Insurance
Private Insurance
Medicaid
Medicare
Other
government
insurance
Not Insured
Distance to Hospital
<=10 miles
11‐50 miles
51‐100 miles
>100 miles
Facility Type
Academic/
Research Program
Community
Cancer Program
(CCP)
Comprehensive
CCP

LS‐SCLC (N = 44,490)
Crude OR
Adjusted OR
(95% CI)
(95% CI)
**
1.00
–
–
0.98 (0.94–1.02)

ES‐SCLC (N = 64,847)
Crude OR
Adjusted OR
(95% CI)
(95% CI)*
**
1.00
–
1.04 (0.99–1.08)
–

1.00
1.57 (1.49–1.65)
3.64 (3.43–3.85)

1.00
1.35 (1.28–1.42)
2.52 (2.38–2.67)

1.00
1.37 (1.27–1.46)
2.51 (2.33–2.71)

1.00
1.13 (1.04–1.23)
1.13 (0.96–1.34)

1.00
1.05 (0.94–1.26)
1.09 (0.94–1.26)

1.00
1.40 (1.31–1.50)
3.24 (3.00–3.49)
**
–
–
–
**
–
–
–

Ref.
0.92 (0.86–0.99)
1.04 (0.90–1.22)

1.00
1.13 (1.04‐1.23)
1.08 (0.91‐1.29)
**
–
–
–

1.00
1.30 (1.18–1.43)
2.12 (2.02–2.24)
0.99 (0.82–1.22)

1.00
1.39 (1.27–1.52)
1.35 (1.27–1.44)
0.89 (0.74–1.08)

1.00
1.09 (0.99–1.20)
1.61 (1.53–1.69)
2.27 (1.91–2.69)

1.00
1.15 (1.05–1.26)
1.09 (1.01–1.16)
2.13 (1.79–2.54)

1.34 (1.19–1.52)

1.47 (1.31–1.65)

1.31 (1.17–1.46)

1.00
0.96 (0.91‐1.00)
1.33 (1.20‐1.48)
1.25 (1.08‐1.45)

1.00
1.01 (0.96‐1.07)
1.44 (1.29‐1.60)
1.41 (1.20‐1.65)

1.00
0.91(0.87‐0.96)
0.92 (0.83‐1.03)
0.99 (0.85‐1.16)

1.40 (1.26–1.56)
**
–
–
–
–

1.00

1.00

1.00

1.00

1.07 (0.95‐1.19)

1.01 (0.90‐1.13)

0.93 (0.83‐1.05)

0.94 (0.83‐1.06)

0.99 (0.90‐1.09)

0.87 (0.79‐0.96)

0.90 (0.81‐0.99)

0.87 (0.78‐0.97)

1.00
1.03 (0.95–1.12)
1.08 (0.92–1.28)
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Table 9. (cont’d)
LS‐SCLC (N = 44,490)
Crude OR
Adjusted OR
(95% CI)
(95% CI)

ES‐SCLC (N = 64,847)
Crude OR
Adjusted OR
(95% CI)
(95% CI)*

Facility Region
Northeast
1.00
1.00
1.00
1.00
0.80 (0.71‐0.89)
0.72 (0.64–0.81)
0.73 (0.65–0.82)
Midwest
0.83 (0.74–0.93)
1.25 (1.12‐1.39)
0.98 (0.87–1.09)
1.00 (0.90–1.12)
South
1.20 (1.08–1.32)
1.22 (1.07‐1.40)
1.04 (0.91–1.19)
1.06 (0.93–1.22)
West
1.23 (1.08–1.40)
Charlson/Deyo
Comorbidity Score
0/none
1.00
1.00
1.00
1.00
1.38 (1.31‐1.45)
1.02 (0.96–1.07)
1.00 (0.95–1.06)
1
1.42 (1.36–1.50)
1.84 (1.71‐1.97)
1.35 (1.26–1.44)
1.30 (1.22–1.40)
2+
2.01 (1.88–2.15)
Year of Diagnosis
2003–2005
1.00
1.00
1.00
1.00
0.89 (0.85–0.94)
0.86 (0.82‐0.92)
0.81 (0.76–0.85)
0.80 (0.76–0.85)
2006–2008
0.74 (0.70‐0.78)
0.66 (0.63–0.70)
0.66 (0.62–0.69)
2009+
0.78 (0.74–0.82)
* Cases diagnosed prior to 2003 were excluded from the analysis due to unavailability of comorbidity
information, and excluding patients who did not receive treatment at the reporting facilities.
** The variable was not included in the final model for LS‐SCLC.

Impact of adherence to treatment guidelines on 5‐year survival
Patients with either LS‐SCLC or ES‐SCLC who received adequate treatment had significantly better
survival than those who received inadequate or no treatment at all (median survival time of 18
months vs. 8 months vs. 2 months in LS‐SCLC, respectively; 8.4 months vs. 2.1 months vs. 0.9
months in ES‐SCLC, respectively) (Table 10). Thirty‐nine LS‐SCLC patients who received adequate
treatment survive at least 2‐year, substantially higher than 16.8% in the group receiving
inadequate treatment. About 19% of the ES‐SCLC patients who received adequate treatment
survived up to two years, as opposed to 6.6% in patients who received inadequate treatment
(Table 11). Unadjusted survival curves by treatment adequacy are presented in Appendix B.
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Table 10. Median survival time (95% CI) of SCLC patients
Median survival time (95% CI), in months
Adequate treatment
Inadequate treatment
No treatment
*Log-rank test

Limited stage

p‐value*

Extensive stage

p‐value*

18.3 (18.0–18.5)

< 0.001

8.4 (8.3–8.5)

< 0.001

8.7 (8.5–9.7)

2.1 (2.0–2.2)

2.2 (2.1–2.4)

0.9 (0.9–0.9)

Table 11. Unadjusted survival probabilities (95% CI) of SCLC patients
Limited stage

Extensive stage

2‐year survival
Adequate treatment

0.392 (0.386–0.398)

0.080 (0.078–0.083)

Inadequate treatment

0.168 (0.161–0.176)

0.034 (0.031–0.038)

No treatment

0.082 (0.073–0.090)

0.021 (0.018–0.024)

The 5‐year survival
Adequate treatment

0.187 (0.182–0.192)

0.022 (0.021–0.024)

Inadequate treatment

0.066 (0.031–0.071)

N/A

No treatment
N/A
0.007 (0.006–0.009)
N/A: no cases survived, or the number was too small to report

After controlling for other covariates, receipt of inadequate treatment doubled the risk of
death in both LS‐SCLC (aHR, 1.93 [95% CI, 1.88–1.98]) and ES‐SCLC (aHR, 2.02 [95% CI, 1.97–2.07])
patients. Patients who did not receive treatment at all had more than three times higher risk of
death (aHRLS‐SCLC = 3.65 [95% CI, 3.52–3.79]; aHRES‐SCLC = 3.22 [95% CI, 3.15–3.30]) (Table 12).
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Table 12. Adjusted Hazard Ratios (aHR [95% CI]) for 5‐year mortality in SCLC

Treatment received
Adequate
Inadequate
No treatment
Sex
Female
Male
Age at Diagnosis, year
< 65
65–74
75+
Race
White
Black
Other
Urban/Rural
Metro
Urban
Rural
Primary Payer
Private Insurance
Medicaid
Medicare
Other government insurance
Not Insured
Facility Region*
Northeast
Midwest
South
West
Charlson/Deyo Comorbidity Score
0/none
1
2+
Year of Diagnosis
2003–2005
2006–2008
2009+

LS‐SCLC
(N = 41,535)

ES‐SCLC
(N = 64,499)

1.00
1.93 (1.88–1.98)
3.65 (3.52–3.79)

1.00
2.02 (1.97–2.07)
3.22 (3.15–3.30)

1.00
1.18 (1.15–1.20)

1.00
1.17 (1.15–1.19)

1.00
1.13 (1.09–1.17)
1.51 (1.46–1.57)

1.00
1.10 (1.07–1.13)
1.41 (1.37–1.45)

1.00
0.96 (0.92–0.99)
0.88 (0.81–0.96)

1.00
0.93 (0.91–0.96)
0.79 (0.74–0.84)

1.00
1.00 (0.97–1.03)
1.03 (0.96–1.10)

1.00
1.01 (0.99–1.03)
1.04 (0.99–1.09)

1.00
1.21 (1.16–1.27)
1.16 (1.13–1.20)
1.17 (1.02–1.22)
1.18 (1.11–1.25)

1.00
1.14 (1.11–1.18)
1.13 (1.10–1.16)
1.13 (1.05–1.21)
1.18 (1.14–1.23)

1.00
1.03 (0.99–1.07)
1.01 (0.98–1.04)
0.99 (0.95–1.04)

1.00
1.09 (1.06–1.11)
1.02 (0.99–1.04)
1.04 (1.01–1.08)

1.00
1.17 (1.14–1.20)
1.45 (1.40–1.50)

1.00
1.18 (1.16–1.20)
1.43 (1.38–1.47)

1.00
0.97 (0.94–0.99)
0.92 (0.89–0.94)

1.00
0.98 (0.96–1.00)
0.97 (0.95–0.99)
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Discussion
As emphasized by the Institute of Medicine (IOM), clinical practice guidelines are essential for
translating evidence to guide the complexities of cancer patients’ care and improve health care
quality and outcomes.51 Using a large hospital‐based cancer registry, this study described the
adherence to stage‐specific guidelines in the treatment of SCLC patients. Our study showed that
2 out of 10 SCLC patients did not receive guideline‐recommended treatment. This is in addition
to the nearly 14% of patients who did not receive any treatment. To put our findings into
perspective, the adherence level found in our study was substantially lower than the level
reported in non‐small cell lung cancer (NSCLC) patients treated at academic institutions affiliated
with a National Cancer Institute‐designated cancer centers, which showed more than 90%
adherence, even in stage IV disease.75 In our study population, improved guideline adherence
over the last 15 years was evident in all stages of SCLC but was least pronounced in ES‐SCLC.
In this study, we were unable to determine whether guideline non‐adherence was largely
attributed to system‐based factors, patients’ clinical conditions, or rather represents patients’
personal choice. Palliative care might partly explain non‐receipt of chemotherapy in ES‐SCLC
patients as nearly one‐third (29.1%) of these patients were recorded as receiving palliative care.
In both LS‐SCLC and ES‐SCLC, the risk of non‐adherence was higher in older patients, uninsured or
Medicare/Medicaid beneficiaries, and patients with higher comorbidity scores. These factors
have also been reported as determinants of guideline non‐adherence in NSCLC and other
cancers.75,76 Guideline adherence in care for LS‐SCLC patients also varied by the geographic
regions of the facilities, with those in the Northeast having a better adherence than those in the
South and the West.
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Age was a strong predictor of non‐adherence in our study population, as has been reported
in studies of multiple cancers.54,76 A higher toxicity rate and side effects following treatment in
older patients have been suggested as key reasons for under‐utilization of standard therapy in
this group.102,103 Elderly patients also tend to have more comorbidities, which are associated with
higher toxicities in treatment.102,104 Thus, there are indications of preference in the treatment of
the elderly population, as oncologists might recommend less aggressive treatment simply due to
the advanced age of the patients. An online survey with 200 oncologists indicated that they are
less likely to choose intensive cancer therapy for older patients, even if the patient is highly
functional and has a low comorbidity score.105 In that study, the oncologists were randomly
assigned one of two surveys with vignettes that were identical except for patient age (< 65 years
or > 70 years). For one of the vignettes describing a case of stage IIA breast cancer patients with
ECOG score of 0 (fully active, able to carry on all pre‐disease performance without restriction),
93% of the oncologists recommended intensive adjuvant treatment for a patient aged 63, but
only 66% would recommend it if the patient was 75‐years‐old. Another study, which analyzed
SEER‐Medicare data, reported the underutilization of chemotherapy in older patients,
independent of their performance status.28
More recent evidence challenges the practice of recommending less aggressive treatment to
older patients solely based on age.102 Despite having a higher rate of toxicity, studies have shown
similar outcomes of standard therapy in the elderly population in comparison to younger
patients.106,107 Furthermore, a report from another study evaluating performance status in 503
lung cancer patients showed no correlation between age and poor performance status.108
However, caution should be taken when evaluating treatment outcomes in the elderly patients,
especially when comparing it with the younger patients; there is a potential selection bias because
the elderly who receive standard therapy are likely in far better health condition than those who
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do not. Thus, the analysis will tend to result in overestimating the benefit among the elderly.
Nevertheless, the fact that a higher number of older patients received inadequate treatment,
while the disease is predominantly in the elderly, calls for more efforts to be directed toward
providing evidence‐based care for this population, as recommended by the IOM.50 Research to
provide predictive assessments to help physicians in determining patients’ fitness for intensive
therapies in this population is essential.
One of the interesting findings from our study was the indication of regional differences in
guideline adherence, independent of other risk factors. This finding was statistically significant
only in LS‐SCLC patients, which required multimodality therapies. Patients who were treated in
the South and the West regions were more likely to receive inadequate treatment, compared to
the Northeast region. An opposite finding was evident among patients treated in the Midwest
region. Our findings might indicate potential disparities in access to quality cancer care, or
represent differences in other underlying factors, or both. Population‐wise, the South region
comprises the largest proportion of residents with less than a high school education and the
lowest quartile of income level. Additionally, variations persist in travel time between primary
physician and referral cancer care, as demonstrated by Onega et al.109 Compared to the Northeast
region, the South has the longest median travel times to the nearest NCI cancer center or
academic‐based care, although the difference was not substantial for travel time to reach any
specialized cancer care. For instance, the median travel time to the nearest NCI cancer center for
a population in the South was 164 min (IQR, 70–272), compared to only 36 min (IQR, 16–75) for
the population in the Northeast. Likewise, the population in the West experience longer travel
times than the Northeast’s population. In terms of healthcare supply; the Northeast region had
the highest per capita oncologists for hospital referral regions (3.2 per 100,000 residents).109
Although the study by Onega et al. showed that patients in the Midwest also had similar
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disadvantages as those in South and West regions, our study showed that patients treated in the
Midwest had better adherence level than patients in the Northeast. Our analysis, however, was
not able to verify the reason for this finding.
Despite the importance of clinical practice guidelines, it should be noted that there are
limitations in the guidelines themselves, as well as the system‐based factors that are associated
with the development and implementation of the guidelines.50 A review conducted by the IOM
showed great variability in the quality of existing clinical practice guidelines (CPGs) in cancer care,
which stems from limited individual scientific studies and limited systematic reviews of the
guidelines upon which the CPGs have been based. On average, the CPGs reviewed by IOM only
met 50% of the IOM standards for practice guidelines. Further, lack of dissemination, the
voluntary nature of guideline implementation, and a lack of monitoring might also contribute to
the limited adoption of existing guidelines.50
Guideline adherence has been hypothesized to lead to improved patient survival. Our study
confirmed this hypothesis in patients with SCLC, regardless of the stage of disease at diagnosis.
Our study also corroborates the work of others with a relatively similar survival benefit evident in
both younger and older patients, although interpretation should be made with caution due to
potential selection bias. These findings highlight the importance of improving guideline adherence
to increase the overall survival of SCLC patients. There is also a need to put more focus on patients’
outcomes beyond survival (e.g., quality of life), especially when dealing with the least curable
cancers, such as SCLC.
Our findings should be interpreted in light of several limitations. The database used in this
study only included hospitals that are accredited by the Commission on Cancer (CoC) of the
American College of Surgeons. These hospitals are mainly larger facilities with higher care
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specialties, which might not be representative of all hospitals in the US. Thus, our findings might
over‐estimate the actual level and trend of guideline adherence in facilities with lower levels of
cancer care specialty facilities. In addition, our analysis used less conservative criteria for
adherence in LS‐SCLC as we did not consider the sequence of chemo‐radiation or type of
chemotherapy agents. Furthermore, the effect of unmeasured confounders of treatment
adherence, such as functional status, cannot be ruled out.

Conclusion
This study provides evidence of moderate guideline adherence level in the care of SCLC patients,
which might have contributed to the relatively modest improvement in the survival of SCLC
patients over the past three decades. Further research is needed to identify factors that
contribute to low adherence, from both the provider and patient viewpoint. Every attempt
should be made to ensure that patients are offered, and have access to, optimal treatment
while keeping patient preferences at the forefront.
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CHAPTER IV: CHARACTERISTICS AND SURVIVAL OF NEVER‐SMOKERS WITH
LUNG CANCER ‐ A VETERANS’ AFFAIRS CENTRAL CANCER REGISTRY ANALYSIS
Abstract
Background: An estimated 16,000 to 24,000 never‐smokers died of lung cancer in the US annually.
Although never‐smokers could benefit from targeted therapy for genetic mutations that
commonly occurred in this population, previous findings on the survival of never‐smokers with
lung cancer, as compared to ever‐smokers, have been conflicting. Methods: Using data from the
Veterans Affairs Central Cancer Registry (VACCR) from 2001 to 2008, we examined the
characteristics and 5‐year survival of never‐smokers with lung cancer, as compared with ever‐
smokers. Cox Proportional Hazards regressions were used to examine the effect of never‐smoking
status on survival. Results: We found that the median age at diagnosis in never‐smokers (73 years,
IQR = 17) was older than in ever‐smokers (68 years, IQR = 17, p‐value < 0.001). The proportion of
females among never‐smokers (3.3%) was almost twice the proportion in ever‐smokers (1.8%).
Adenocarcinoma is the most common histology among never‐smokers (34.7%), with a higher
proportion than in ever‐smokers (26.0%). After adjusting for sex, alcohol use, stage at diagnosis,
histology, and treatment modality, an increased risk of death associated with smoking status was
only significant in patients diagnosed at less than 65‐years‐old (aHR, 1.19 [95% CI, 1.06–1.33]),
but not in the older group (aHR, 1.02 [95% CI, 0.95–1.09]). Conclusion: Our study demonstrated
differences in the clinical and demographic characteristics between never‐ and ever‐smokers with
lung cancer. Never‐smokers, in general, do not experience better survival than ever‐smokers.
Future research should focus on understanding the etiology and early symptoms of lung cancer
in never‐smokers, and establish screening and early diagnosis methods.
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Introduction
An estimated 10–25% of lung cancer cases worldwide, and 10–15% in the United States (US),
occur among never‐smokers.6,7 When considered as a single disease, separate from incidence in
ever‐smokers, lung cancer in never‐smokers (LCINS) is among the top ten leading causes of US
cancer deaths, accounting for an estimated 16,000 to 24,000 deaths annually.58
LCINS is clinically important as it presents with tumor biology and prognosis that are
considered distinct from lung cancers in ever‐smokers.13 Never‐smokers are more often
diagnosed with adenocarcinoma and are more likely to exhibit certain gene mutations that
respond well to targeted therapy.59 Thus, never‐smokers with lung cancer are likely to have better
survival than ever‐smokers. However, the absence of smoking history might contribute to delays
in diagnosis and lead to never‐smokers being diagnosed at later stages of lung cancer.110 From a
psychological viewpoint, as a commonly perceived self‐inflicted disease, lung cancer creates an
unjust stigma for never‐smokers who are diagnosed with the disease, which has been associated
with delays in seeking medical help among lung cancer patients.111,112 These clinical and
psychological implications highlight the importance of studying LCINS.
Despite the importance of LCINS, the epidemiology and outcomes of never‐smokers with lung
cancer in comparison to ever‐smokers remain inconclusive. The gap in research on LCINS is partly
related to the absence of information on smoking status in most population‐based registries,
making research with large sample sizes of never‐smokers particularly challenging. A better
understanding of LCINS is particularly relevant in a population that is at a high‐risk for non‐
tobacco‐related exposures, such as the veterans. Although the smoking prevalence is higher in
Veterans compared to the general population, 71,113 Veterans are often exposed to other cancer
risk factors during their services, such as Agent Orange, radon, asbestos, depleted uranium, and
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other battlefield emissions. The high smoking prevalence in active military members could also
pose never‐smoker veterans at high risk of second‐hand smoking exposure during service.
In this study, we analyzed data from the Veterans Affairs (VA) healthcare system to investigate
the demographic and clinical characteristics and mortality of never‐smokers with lung cancer. An
improved understanding of LCINS is important not only for the development and delivery of
efficient and effective preventive measures but also to increase the awareness of the clinical
community and the public about the risk of lung cancer in never‐smokers.

Methods
This study is a retrospective data analysis of lung cancer cases diagnosed at the Veterans Affairs
Medical Centers (VAMCs) from 2001 to 2008. The cases were identified from the Veterans Affairs
Central Cancer Registry (VACCR); a database consisting of information on cancer diagnosis and
treatment at each of VAMC. Cancers diagnosed at VA facilities represent approximately 3% of the
total cancer incidence in the US.114 The VACCR database collects information on smoking status,
which is not available in most cancer registries. From the database, we abstracted information on
smoking status, age, sex, race, alcohol use, histology, and treatment modality. We categorized
the self‐reported smoking status into never‐smokers and ever‐smokers. The latter category
includes both former and current smokers.

Study population
Only patients with invasive lung cancer and complete information on smoking status were
included in the analysis. The definition of never‐smokers in the VACCR is similar to the National
Health Interview Survey, which is defined as having smoked fewer than 100 cigarettes in a
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lifetime.115 This study was approved by the Institutional Review Board (IRB) of the Veterans Health
Administration.

Statistical analysis
Descriptive analyses included all lung cancer cases, while the survival analysis was limited to non‐
small cell lung cancer (NSCLC). Descriptive statistics of categorical variables are presented as
proportions while continuous variables are presented as medians with the relevant inter‐quartile
range. Chi‐square and t‐tests were used to analyze the association between each predictor and
smoking status, as applicable. In the survival analysis, the primary predictor was smoking status,
and the primary outcome was 5‐year survival. Survival time was defined as the time from the date
of diagnosis to the date of death or the date of the last contact. Median survival time was
estimated using Kaplan‐Meier estimates.
We tested a two‐way interaction between smoking status and age, and between smoking
status and stage at diagnosis, on survival. A significant interaction was only identified with age
groups: (a) less than 65 years, and (b) 65 years and beyond (p = 0.018). Hence, the multivariable
survival analyses were performed separately for each of the age groups. The 65 years cut‐off was
chosen based on the commonly accepted definition for elderly. We also performed analyses by
stage at diagnosis to allow for comparison with findings from previous studies. Additionally, we
compared the effect of smoking status on survival in lung adenocarcinoma and other histology
types to investigate the specific survival benefit of adenocarcinoma. Prior to the analyses, we
assessed the Proportional Hazards (PH) assumption to determine whether the hazards ratio (HR)
for each predictor was constant over time. For this purpose, the graphical approach and
Schoenfeld’s test were applied. We found that the violation of PH assumption was negligible, and
thus, Cox Proportional Hazards regressions were used. The significance level for all analyses was

66

set at a p‐value < 0.05. All statistical analyses were performed using the statistical software
package SAS, version 9.2 (SAS Institute Inc., Cary, NC).

Results

Patients’ characteristics by smoking status
There were 60,140 patients with lung cancer recorded in the VACCR from 2001 to 2008. We
excluded 273 cases whose stage at diagnosis was either 0 or occult. A total of 59,867 cases were
eligible for this study, of which 4,980 cases (8.3%) were excluded due to missing information on
smoking status. A total of 54,887 cases were included in the analysis. The median follow‐up time
of the study population was 7 months (IQR = 12).
Figure 8. Selection of the study population
Lung cancer diagnosed from 2001 to
2008 (N = 60,140)

Excluded cases
The stage at diagnosis was either 0 or occult (N = 273)

Eligible cases (N = 59,867)
Missing information on smoking status (N = 4,980)
Analyzed – patients’ characteristics
by smoking status (N = 54,887)
- Small Cell Lung Cancer (N = 7,390)
- Unknown histologic type (N = 67)
Analyzed – survival of NSCLC patients
(N = 47,430)

Never‐smokers comprise 3.6% (1,970 out of 54,887 lung cancer cases) of lung cancer patients
diagnosed in the VA health system. The study population was predominantly male (98.2%) and
white (81.8%). The demographic and clinical characteristics of lung cancer patients were
significantly different when comparing smoking status groups. Never‐smokers were diagnosed
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with lung cancer at an older age (median of 73 years [IQR = 17]) than ever‐smokers (median of 68
years [IQR = 15]). The proportion of female never‐smokers (3.3%) was almost twice the proportion
in ever‐smokers (1.8%). A higher proportion of adenocarcinoma was found in never‐smokers
(34.7%) than in ever‐smokers (26.0%), and the opposite trend was detected for squamous cell
carcinoma (21.4% and 29.2%, respectively). The difference in the cancer stage at diagnosis
between the groups was negligible (Table 13).
Table 13. Characteristics of lung cancer patients in the VA health system by smoking status
Characteristics
Median age at diagnosis (IQR),
years
Age group
<40 years
40—49 years
50—59 years
60—69 years
70+ years
Sex
Male
Female
Not recorded
Race
White
Black
Other
Not recorded
Alcohol use
Never
Former
Current
Not recorded

Never‐smokers
(N = 1,970)
n (%)
73 (IQR =
17)

Ever‐smokers
(N = 52,917)
n (%)
68 (IQR = 15)

Total
(N = 54,887) p‐value
n (%)
69 (IQR = 15) < 0.001
< 0.001

5 (0.2)
41 (2.1)
287 (14.6)
456 (23.1)
1,181 (60.0)

26 (0.1)
1,193 (2.2)
10,905 (20.6)
16,989 (32.1)
23,804 (45.0)

31 (0.1)
1234 (2.2)
11,192 (20.4)
17,445 (31.8)
24,985 (45.5)
< 0.001

1,902 (96.6)
66 (3.3)
2 (0.1)

51,975 (98.2)
936 (1.8)
6 (0.01)

53,877 (98.2)
1,002 (1.8)
8 (0.01)
0.003

1,604 (81.4)
308 (15.6)
31 (1.6)
27 (1.4)

43,268 (81.8)
8,496 (16.1)
441 (0.8)
712 (1.4)

44,872 (81.8)
8,804 (16.1)
472 (0.9)
739 (1.4)
< 0.001

1,539 (78.1)
89 (4.5)
250 (12.7)
92 (4.7)

14,225 (26.9)
13,690 (25.9)
18,804 (35.5)
6,198 (11.7)

15,764 (28.7)
13,779 (25.1)
19,054 (34.7)
6,290 (11,5)
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Table 13. (cont’d)
Characteristics
Histology
Squamous
Adenocarcinoma
Large cell
Non‐small cell carcinoma,
NOS
Other NSCLC
Small cell lung cancer
Other specified histology
Unknown
Stage at diagnosis
I and II
III
IV
Not recorded
Treatment
No surgery/radiation/
chemotherapy
Surgery only
Radiation only
Chemotherapy only
Chemo‐radiation
Surgery and chemotherapy
and/or radiation
Not recorded

Never‐smokers
(N = 1,970)
n (%)

Ever‐smokers
(N = 52,917)
n (%)

Total
(N = 54,887)
n (%)

422 (21.4)
684 (34.7)
37 (1.9)
343 (17.4)

15,439 (29.2)
13,749 (26.0)
1,300 (2.5)
9,766 (18.5)

15,861 (28.9)
14,433 (26.3)
1,337 (2.4)
10,109 (18.4)

289 (14.7)
191 (9.7)
3 (0.2)
1 (0.1)

5,407 (10.2)
7,199 (13.6)
19 (0.04)
38 (0.1)

5,696 (10.4)
7,390 (13.5)
22 (0.04)
39 (0.1)

519 (26.4)
448 (22.7)
814 (41.3)
189 (9.6)

14,089 (26.6)
14,123 (26.7)
22,199 (42.0)
2,506 (4.7)

14,608 (26.6)
14,571 (26.6)
23,013 (41.9)
2,695 (4.9)

p‐value
< 0.001

0.030

< 0.001
731 (37.1)

15,529 (29.4)

16,260 (29.6)

286 (14.5)
252 (12.8)
297 (15.1)
286 (14.5)
92 (4.7)

7,593 (14.4)
8,229 (15,6)
8,374 (15.8)
9,943 (18.8)
2,895 (5.5)

7,879 (14.4)
8,481 (15.4)
8,671 (15.8)
10,229 (18.6)
2,987 (5.4)

26 (1.3)

354 (0.7)

380 (0.7)

IQR: Interquartile range; NOS: Not otherwise specified

Survival of NSCLC patients by smoking status
Only 18% of the NSCLC patients survived for at least 5 years. After adjusting for sex, alcohol use,
stage at diagnosis, histology, and treatment modality, an increased risk of death associated with
smoking status was only statistically significant in patients diagnosed at less than 65‐years‐old
(aHR, 1.19 [95% CI, 1.06–1.33]), but not in the older group (aHR, 1.02 [95% CI, 0.95–1.09]) (Table
14).
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Table 14. Adjusted Hazard Ratios (aHR [95% CI]) for 5‐year mortality by age group, NSCLC
Characteristics
Smoking status
Ever‐smokers vs. Never‐smokers (Ref)
Sex
Male vs. female (Ref)
Alcohol consumption
Never
Former
Current
Stage at diagnosis
Stage I and II
Stage III
Stage IV
Histology
Squamous
Adenocarcinoma
Large cell
Non‐small cell carcinoma, NOS
Other NSCLC
Treatment
Surgery and chemotherapy and/or radiation
Surgery only
Radiation only
Chemotherapy only
Chemo‐radiation
No surgery/ chemotherapy/ radiation

Age < 65 years old
(N = 18,383)

Age 65+ years old
(N = 23,766)

1.19 (1.06–1.33)

1.02 (0.95–1.09)

1.14 (1.01–1.30)

1.08 (0.94–1.24)

1.00
1.02 (0.97–1.07)
1.00 (0.96–1.05)

1.00
1.06 (1.03–1.10)
0.99 (0.96–1.03)

1.00
2.03 (1.91–2.16)
3.69 (3.47–3.92)

1.00
1.88 (1.81–1.96)
3.13 (3.01–3.26)

1.00
0.99 (0.95–1.04)
1.13 (1.02–1.25)
1.06 (1.01–1.11)
1.06 (0.99–1.13)

1.00
1.00 (0.97–1.04)
1.20 (1.10–1.31)
1.05 (1.01–1.09)
1.04 (0.99–1.09)

1.00
1.20 (1.08–1.32)
3.35 (3.07–3.65)
1.66 (1.52–1.81)
1.61 (1.48–1.75)
4.09 (3.76–4.45)

1.00
1.18 (1.08–1.29)
2.57 (2.36–2.80)
1.57 (1.44–1.71)
1.47 (1.35–1.60)
3.47 (3.20–3.77)

A multivariable analysis stratified by stage at diagnosis detected statistically significant
association only between smoking status and survival in patients diagnosed with stage III cancer
(aHRstage I and II = 1.05 [95% CI, 0.92–1.18]; aHRstage III = 1.14 [95% CI, 1.02–1.27]; aHRstage IV = 1.02
[95% CI, 0.94–1.10]) (Table 15). Stratified analyses by histology, adjusted for other predictors,
showed that the survival benefit of never‐smokers was statistically significant only in patients with
lung adenocarcinoma (aHR, 1.21 [95% CI, 1.10–1.34]), but not in other histologies (aHR, 0.99 [95%
CI, 0.92–1.06]) (Table 16).
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Table 15. Adjusted Hazard Ratios (aHR [95%CI]) for 5‐year mortality in never‐smokers
compared to ever smokers NSCLC patients, by stage at diagnosis*

Ever‐ vs. never‐smokers (Ref)

Stage I & II
(N = 13,942)

Stage III
(N = 12,599)

Stage IV
(N = 18,510)

1.05 (0.92–1.18)

1.14 (1.02–1.27)

1.02 (0.94–1.10)

*The model was adjusted for age, sex, alcohol consumption, histology, and treatment modality

Table 16. Adjusted Hazard Ratios (aHR [95%CI]) for 5‐year mortality in NSCLC patients, by
histology*

Ever‐ vs. never‐smokers (Ref)

Adenocarcinoma
(N = 12,334)

Non‐adenocarcinoma
(N = 27,364)

1.21 (1.10–1.34)

0.99 (0.92–1.06)

*The model was adjusted for age, sex, alcohol consumption, stage at diagnosis, and treatment modality

A comparison of prognostic factors between never‐ and ever‐smoker groups (Table 17)
showed that most of the predictors assessed in this study showed a relatively similar effect on the
survival of each never‐ and ever‐smokers group, except for sex and histology. In never‐smokers,
there was an indication of a lower risk of death in males, although it was not statistically
significant. In contrast, males in the ever‐smoker group had a significantly higher risk of death
than their female counterparts. In the never‐smoker group, patients with adenocarcinoma had
about 16% lower risk of death than patients with squamous lung cancer (aHR, 0.84 [95% CI, 0.72–
0.98]), but this association was not evident in ever‐smoker groups (Table 17).
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Table 17. Adjusted hazard ratios (aHRs [95%CI]) of 5‐year mortality by smoking status, NSCLC
Characteristics
Age at diagnosis
<65 years vs. 65+ years old (Ref)
Sex
Male vs. female (Ref)
Alcohol consumption
Never
Former
Current
Stage at diagnosis
Stage I and II
Stage III
Stage IV
Histology
Squamous
Adenocarcinoma
Large cell
Non‐small cell carcinoma, NOS
Other NSCLC
Treatment
Surgery and chemotherapy and/or radiation
Surgery only
Radiation only
Chemotherapy only
Chemo‐radiation
No surgery/ chemotherapy/ radiation

Never‐smokers
(N = 1,775)

Ever‐smokers
(N = 38,198)

0.83 (0.72–0.094)

0.96 (0.94–0.98)

0.87 (0.62–1.21)

1.15 (1.04–1.26)

1.00
1.01 (0.79–1.30)
1.13 (0.96–1.34)

1.00
1.05 (1.02–1.08)
0.99 (0.97–1.03)

1.00
1.78 (1.49–2.12)
3.34 (2.82–3.95)

1.00
1.94 (1.87–2.01)
3.35 (3.23–3.46)

1.00
0.84 (0.72–0.98)
1.33 (0.91–1.94)
0.99 (0.84–1.17)
0.95 (0.78–1.15)

1.00
1.01 (0.98–1.04)
1.16 (1.08–1.24)
1.06 (1.03–1.09)
1.05 (1.01–1.09)

1.00
0.98 (0.69–1.40)
2.28 (1.63–3.18)
1.30 (0.92–1.82)
1.44 (1.03–2.01)
3.21 (2.33–4.42)

1.00
1.22 (1.14–1.31)
2.93 (2.76–3.12)
1.65 (1.55–1.76)
1.56 (1.47–1.66)
3.79 (3.57–4.02)

Discussion
Exposures to risk factors other than active tobacco smoking during military services could pose a
critical concern for the risk of lung cancer among never‐smoker Veterans. Although our study
indicated a small proportion of LCINS in the VA health system in 2001–2008 (3.6%), this number
translates to more than 1,800 lives affected by the detrimental effects of the disease. Our study
reported differences in demographic and clinical profiles by smoking status and, to some extent,
indicated different findings compared to studies in the general population.
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Previous studies on the epidemiology of LCINS yielded inconsistent results. Several studies
reported a younger age at diagnosis among never‐smokers than ever‐smokers,110,116 but others
found the opposite or no difference.60,63 In our study population, never‐smokers were diagnosed
at an older age than ever‐smokers. Our findings substantiate previous studies that reported
gender variations in LCINS.65,110 Although the number of females in our study was considerably
small, the proportion of lung cancer in never‐smoker females was nearly twice that of ever‐
smokers. Gender variation in LCINS has been linked to the role of estrogen in the pathogenesis of
lung cancer.13,62
The histologic types of LCINS in our study population appeared to be distinct from findings in
most previous studies. Although adenocarcinoma is the most common histologic type (35.7%),
consistent with previous studies, the proportion was substantially lower than as reported by
previous studies (50–87%).65,116,117 We also found a relatively high share of squamous carcinoma
(20.9%) and small‐cell lung cancer (9.7%); two histologic types that are strongly associated with
active tobacco smoking. A review of 17 published studies found 3.4‐times more adenocarcinomas
than squamous cell carcinomas in never‐smokers.13 Although some might argue that the high
proportion of ‘not otherwise specified’ (NOS) category in our study might confound the findings,
this proportion of NOS group was relatively similar to what has been reported elsewhere.118 The
different histological type in our study was likely due to the predominantly male patient
composition, as adenocarcinoma has been reported to be higher among females.118 Moreover,
our findings resemble a study among non‐smoking male construction workers with lung cancer in
Sweden that found 40% of cases were adenocarcinomas, and 19% were squamous cell
carcinomas.61 Hence, our study points to the importance of gender variation in the histology of
LCINS, and further, the need to investigate the effect of occupational‐related exposures on tumor
histology in the Veteran population.
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The need to investigate occupational‐related exposures is heightened by the indication that
genetic susceptibility might not play a major role in the etiology of LCINS in our study population.
Previous studies found genetic susceptibility in LCINS patients who had early onset of disease (less
than 50‐years‐old). In our study population, the proportion of never‐smokers diagnosed with lung
cancer at younger than 50‐years‐old was only 2.7%, which was not statistically different from
ever‐smokers (2.3%). Our study did not find substantial differences in the stage at diagnosis by
smoking status. Patients in the VA health system have been reported to be diagnosed at an earlier
stage of cancer, compared to the general population, suggesting adequate access to preventive
and chronic disease care within the Veterans Health Adminsitration (VHA).70,119
The limited information in our data did not allow us to investigate factors associated with the
incidence of LCINS, but several risk factors have been discussed in the literature. Radon and
second‐hand smoking have been considered as major contributors to LCINS in the US.7 The
veterans, however, are different from the general population in regards to their exposure to
cancer risk factors during service. Although smoking prevalence among active military members
has declined, historically the prevalence was very high. A survey in 1980 showed that 51% of active
military members smoked within 30 days preceding the survey.71 The high smoking prevalence
during service could lead to high exposure to environmental tobacco smoke. Deployed veterans
were also exposed to service‐related risk factors, such as depleted uranium, Agent Orange,
asbestos, burn pits, and diesel exhaust. These substances have been suspected to cause adverse
health outcomes, although the association with lung cancer has been limited, mixed or not
proven. The Institute of Medicine (IOM) concluded that there was limited or suggestive evidence
that Agent Orange used in the Vietnam War was associated with lung cancer.120 This is of
particular concern for our study since more than one‐third of VHA users (36%) are veterans who
were deployed during the Vietnam War era.71 Abundant evidence has also shown the effect of
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radiation on lung cancer, but IOM suggests that the military members post‐World War II were
more likely exposed to a low dose of radiation if they were exposed at all, which does not pose
harm.71 Given the methodological challenges in investigating the effect of service‐related
exposures on the occurrence of lung cancer, the influence of those exposures could not be
completely ruled out.
LCINS has been found to have a better prognosis than ever‐smokers in some studies, but not
in others.65,116,121 Our multivariable analysis found age‐ and histologic‐specific effects of smoking
status on the 5‐year survival of NSCLC patients. The survival differences were specific to patients
who were diagnosed at less than 65‐years‐old and among patients with lung adenocarcinoma.
The absence of a significant effect of smoking status among the elderly is likely explained by the
higher disease burden coupled with the lower functionality due to aging, or competing risks of
death from other causes.
One of the explanations for survival differences by smoking status is that, compared to never‐
smokers, ever‐smokers tend to have smoking‐related comorbidities that might preclude them
from receiving adequate treatment, leading to poor prognosis. Also, a higher portion of never‐
smokers with lung adenocarcinoma exhibit activating mutations in the epidermal growth factor
receptor (EGFR) gene. The EGFR mutation itself is a prognostic factor in lung cancer since patients
with this mutation demonstrate good clinical outcomes when treated with the EGFR‐tyrosine
kinase inhibitor (TKI). A review by Sun et al. reported EGFR mutations in 58% of never smokers,
but only in 13% of ever‐smokers.13 However, a study among the veteran population found that
the proportion of clinically actionable EGFR mutations among never‐smoker veterans with lung
adenocarcinoma (28.6%) appeared to be lower than in the general population, which might
explain the limited survival benefit among never‐smokers.122 In addition, although EGFR
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mutations have been found to be higher among females, the association between gene mutations
and unique risk factors among the veterans deserves further investigation.
Findings from our study raise the question of whether LCINS in veterans differs from the
general population and highlights the need for further research on the epidemiology and
outcomes of LCINS among veterans. It should be noted that our data includes patients diagnosed
before the professional guidelines on EGFR mutation testing were endorsed in 2011.123 However,
one study of NSCLC patients in the VAMCs in 2011–2013 indicated variability in genetic
consultation services and documented a number of cases that did not comply with the clinical
guidelines for targeted therapy, which could influence the quality of care. 122 Fortunately, in 2015,
the Department of Veterans Affairs launched a National VA Precision Oncology Program to
improve genetic diagnostic testing for personalized medicine.124 Going forward, it is crucial to
ensure that the program is implemented comprehensively to ensure the maximum benefit for
veterans.
Gaps in the understanding of LCINS remain and point to opportunities for further research.
Identification and validation of biomarkers for early diagnosis of LCINS could improve clinical
practice. Given the absence of extensive cellular and molecular damages caused by tobacco,
studies focusing on never‐smokers could help shed light on the etiology of lung cancer, beyond
active smoking. Also, as part of promoting research on LCINS, cancer registries need to consider
incorporating smoking status information.
To our knowledge, this study is the first to discuss LCINS in the veteran population specifically.
Our study has the advantage of a large number of never‐smokers, unlike previous studies.
Nevertheless, our findings were subject to several limitations. First, our study population might
not be generalizable to all US veterans, since only about 30% of the veterans were enrolled in the
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VA healthcare system.81 The enrolled Veterans tended to have lower socio‐economic status and
poorer socio‐economic and health conditions.81 Another limitation was the use of self‐reported
smoking status, which is subject to misclassification. However, a validation study of self‐reported
smoking status indicated a non‐significant misclassification.115 The database that we used does
not provide information on important predictors, such as secondhand smoking and occupation‐
related exposures, and thus, limited our ability to explain the epidemiological and clinical
differences found in this study. We analyzed data for the period of 2001–2008, which might not
have reflected the current situation of VA patients. However, a more recent analysis of NSCLC
patients undergoing EGFR testing from 2011 to 2013 showed a relatively similar proportion of
never‐smokers (4%).122
Our study was not intended to solely link lung cancer incidence among veterans with service‐
related exposures. We were aware that veterans are likely to be exposed to occupational or
residential risk factors in their later life after being discharged from the military.

Conclusion
Given the decline in the prevalence of smoking in the US and other Western countries, we expect
an increased proportion of never‐smoker patients with lung cancer. Finding ways to reduce LCINS
might serve as the next key step in reducing the overall incidence of lung cancer. Future research
should focus on understanding the etiology and early symptoms of LCINS, and establish a means
for screening and early diagnosis. Physicians’ understanding of these symptoms and risk factors
will further stress the importance of including lung cancer as a possible suspect in never‐smokers
who present with symptoms that might lead to lung cancer. Therefore, diagnosis and
interventions could be made earlier to ultimately promote better outcomes.
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CHAPTER V: DISCUSSION
The past decades have witnessed major advances in medical science, including the treatment of
lung cancer. Nevertheless, more than half of lung cancer patients die within 1 year of diagnosis.3
Although multiple prognostic factors for lung cancer patients’ survival have been discussed in the
literature, gaps in knowledge remain for some of the factors, for which evidence has been either
limited or inconclusive. This dissertation focused on the effect of extended time‐to‐treatment,
non‐adherence to treatment guidelines, and never‐smoking status on the overall survival of lung
cancer patients. Since time‐to‐treatment and adherence to treatment guidelines are modifiable,
a better understanding of those factors could help improve patients’ survival. Of particular
interest, we also studied the effect of never‐smoking status on the survival of NSCLC patients amid
concerns about the distinct biology of lung cancer in never‐smokers.

5.1 Summary of Findings from the Present Study and Its Relevance to the Literature
In the first study (Chapter II), we examined the effect of extended time‐to‐treatment on the
survival of patients diagnosed with NSCLC. Despite the presumed association between treatment
delay and patients’ survival, previous studies have shown mixed results. Limited sample size, lack
of adjustment for important confounders, and variation in the cut‐off point of treatment delay
are among the potential explanations for the inconsistent findings. The NCDB offers the
opportunity to study a large sample of NSCLC patients and thereby address some of those
challenges.
We hypothesized that an extended time‐to‐treatment is associated with reduced survival.
Results of the multivariable analyses, however, showed that patients who waited longer than the
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commonly recommended interval (i.e., more than 4 weeks after diagnosis) had a lower risk of
death, compared to those who began treatment within the first 4 weeks of diagnosis. These
results were consistent across different stage groups. The effect was larger in patients with
metastatic cancer, while the Hazard Ratios (HRs) in patients diagnosed with early‐stage cancer
were close to the null value (HR = 1), suggesting the differences in risk of death in the latter group
of patients might not be clinically meaningful. However, a subset analysis among early‐stage
patients who received surgery only revealed findings in the opposite direction. Findings among
early‐stage patients who received surgery only support our hypothesis that extended time‐to‐
treatment is associated with poorer survival.
Our study corroborates findings from previous studies but contradicts with several
studies.39,95 Lower hazard ratios associated with treatment delay have also been reported in
previous studies of lung and other cancers.46,47,84 These findings could reflect the situation in
which patients with a longer time‐to‐treatment might receive a more comprehensive evaluation,
especially a detailed analysis of molecular markers within their tumors, thus leading to better
survival. An alternative explanation from a methodological point‐of‐view is that our findings could
also be affected by confounding by severity, a condition in which the exposure (in our case, the
time‐to‐treatment) is driven by the disease severity.125,126 Patients with advanced disease or
poorer disease biology might receive expedited treatment due to the severity of their condition.
Thus, these patients inherently have a worse prognosis compared to other patients, regardless of
the time to initiate treatment. To minimize the effect of confounders, we have adjusted multiple
factors and stratified our analysis by stage at diagnosis. However, severity or patients clinical
conditions may largely vary within the same stage at diagnosis, and thus, the stratification by
stage may not be sufficient to reduce the effect of any unmeasured confounder.
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In our study population, 42.6% of NSCLC patients began treatment more than 4 weeks after
diagnosis. A longer time‐to‐treatment could be a consequence of more extensive evaluation and
coordination of care, as treatment of lung cancer often involves a multidisciplinary team and
multiple assessments. A longer median time‐to‐treatment in patients with early‐stage cancer
compared to those with metastatic cancer, as demonstrated in this study, could also be associated
with preoperative evaluation.127 Lung cancer resections require thorough assessments, including
cardiovascular evaluation, and assessment of lung function and exercise capacity.128,129 The
process is then followed‐up with a re‐evaluation to ensure patients’ eligibility for resection.128
Since the majority of lung cancer patients are either former or current smokers; they are at high
risk for cardiovascular disease and other smoking‐related comorbidities. Such conditions require
further evaluation, which might lead to a longer time‐to‐treatment interval. Also, to improve their
lung capacity, patients who are current smokers are also advised to quit smoking within 8 weeks
before surgery.130 Delayed treatment can also be caused by non‐clinical factors, such as insurance,
or merely patients’ choice to begin treatment. Although multiple factors can affect time‐to‐
treatment, it is important to ensure that patients do not experience treatment delay for any
avoidable reasons.
Besides timeliness of care, another important effort to improve patient outcomes is to ensure
patients receiving care that has been proven effective and incorporated into clinical practice
guidelines. This premise led us to the second study (Chapter 3), in which we examined the trend
and predictors of non‐adherence to treatment guidelines among SCLC patients, and its impact on
patients’ survival. Use of the NCDB enabled our study to portray a broad picture of treatment
provision as the database represents nearly 70% of cancer patients in the US and spanning for a
long period. Our study found a moderate, but increasing, level of adherence to treatment
guidelines for SCLC patients between 1998 and 2012. Among patients who are deemed eligible
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for the treatment, 78.9% of LS‐SCLC and 87.4% of ES‐SCLC patients received treatment that
adheres to the guidelines. Those proportions, however, are lower than adherence to treatment
guidelines in NSCLC and other cancers, such as colon cancer.75,76 The multivariable analysis
showed that LS‐SCLC and ES‐SCLC patients of older age, higher comorbidity score, and uninsured
or using Medicare/Medicaid had a significantly higher risk of receiving treatments that do not
adhere to the guidelines. Our findings are consistent with previous studies.75,76
Our study found that facility region was an independent predictor for non‐adherence.
Patients who were treated in the South and the West regions were more likely to receive
treatments that do not adhere to the guidelines, compared to the Northeast region. In Chapter
III, we discussed how this finding might reflect potential disparities in access to quality cancer
care, such as the population’s socioeconomic status and travel time. On the other hand, patients
who were diagnosed/treated in facilities in the Midwest region were more likely to receive
guidelines‐adherence, compared to those of the Northeast region. This finding is relatively
unexpected given the fact that, compared to the Northeast, the oncologist per capita is lower and
travel time to the referral hospitals is longer in the Midwest.109 Although we were not able to
explain this finding, it should be noted that the database used for this study may over‐represent
patients from the urban areas, and thus, do not provide a comprehensive picture about the
Midwest area as a whole. In our study, for example, only 3.4% of patients from the Midwest lived
in the rural areas.
In this study, patients who do not receive guideline‐recommended treatment had twice the
risk of death of those who received guideline‐recommended treatment, after adjusting for other
covariates. Our findings showed that the reduction in survival among patients receiving
inadequate treatment was consistent in both LS‐SCLC and ES‐SCLC patients and in both younger
(≤ 65‐years‐old) and the elderly (>65‐years‐old) patients.
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Our third study (Chapter IV) examined the survival among never‐smoker patients in the VA
health system, who were diagnosed with lung cancer. The VACCR database is among the very
limited secondary data that collect information on smoking status and allowed us to study a
specific population that is presumed to have a higher level of exposure to occupational risk factors
for lung cancer. With a relatively large number of never‐smokers, the VACCR provides a unique
opportunity to overcome a major limitation of previous studies that had a small sample size. To
our knowledge, this is the first study to focus on the characteristics and survival of never‐smokers
diagnosed with lung cancer in the US Veteran population. A previous study by different authors
examined the effect of smoking on survival in the same population, but the study was not focused
on never‐smokers.131
The proportion of LCINS in our study population was only 3.6%; however, this proportion
translates to a significant number (more than 1,800 patients in 2001–2008). The demographic and
clinical characteristics of never‐smokers with lung cancer in our study population appears to be
different from studies of LCINS in the general population. For example, although the percentage
of females in the never‐smoker group is higher than among ever‐smokers, the percentage is
relatively lower than what we would have expected. However, the fact that female patients were
only 2% of our study population limited our ability to examine gender differences.
In addition to second‐hand smoking and occupational‐related exposures during services,
another potential factor that could increase the risk of lung cancer among never‐smokers is the
presence of Chronic Obstructive Pulmonary Disease (COPD). COPD has been shown to drive the
occurrence of lung cancer through inflammation of the lung tissue. Although COPD is closely
associated with smoking, Veterans are at high risk for development of COPD due to occupational‐
related exposures in addition to tobacco smoking, which could increase their risk for lung
cancer.132
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Our study did not demonstrate a survival benefit among never‐smokers in general. A subset
analysis, however, showed a positive effect on survival among never‐smokers diagnosed at ages
of less than 65 years. The absence of survival benefit among older patients may be associated
with the lower physical functions among this group. A better survival associated with never‐
smoking status was also seen among patients with adenocarcinoma, independent of age. Findings
from our study differ from several previous studies that have reported lower mortality risk among
never‐smokers regardless of the age at diagnosis.121,133,134 Nevertheless, our study offers an
association between smoking and survival of lung cancer patients that is consistent with the
biology of lung cancer. It appears that, given the fatality of lung cancer, once a patient is diagnosed
with the disease, smoking status is no longer a strong prognostic factor.

5.2 Implications
The three factors investigated through this dissertation have important clinical and public health
implications. Our first two studies provided evidence on the importance of two important
modifiable factors related to the quality of cancer care that has been highlighted by IOM.

50,51

Findings from the third study shed light on the importance of never‐smokers among the lung
cancer patient population.
Time to treatment initiation appears to be crucial for early‐stage patients with a resectable
tumor. It is prudent to ensure that this group of patients receive surgery within the first four
weeks of diagnosis. For the rest of the patient population, however, extended time‐to‐treatment
does not appear to have an adverse effect on survival. More comprehensive assessments,
although possibly resulting in extended waiting time, are likely to bring more survival benefit to
the patients rather than rushing the treatment. The survival benefit will likely affect patients with
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advanced cancer who exhibit particular molecular abnormalities. This patient group would likely
benefit from targeted therapy. Targeted therapy, however, requires additional time to perform
mutation testing, which will guide clinicians in determining the type of targeted drugs that are
most likely to work for the patient. In practice, the molecular testing can take up to several weeks.
The window period between diagnosis and treatment initiation gives patients and their
informal caregivers (e.g., family) time to discuss their treatment options with their clinicians, to
seek second opinions, and then decide the best treatment option. However, the length of
diagnosis‐to‐treatment interval time should not be compromised. Moreover, the diagnosis‐to‐
treatment interval should be seen as a part of a cancer care continuum that starts with symptom
evaluation. It should be kept in mind that prior to receiving treatment after diagnosis, most
patients might have experienced a waiting time between symptom evaluation and diagnosis that
might affect their disease progression.
Given findings from this study as well as other previous studies with a similar notion, there
might be a need to revisit existing benchmarking for time‐to‐treatment that has been
implemented in several developed countries. In countries such as the United Kingdom and
Canada, facilities that do not meet the standard minimum waiting time can be penalized, or at
the very least affect their performance indicator. While time‐to‐treatment benchmarks are
important, it is crucial to ensure that the benchmarks do not hinder optimal evaluation for
treatment planning.
As treatment delay can also be influenced by facility‐ and clinician‐related factors, it is
important to emphasize that facilities should have adequate resources to perform the tests
needed or have access to other external facilities that could perform the assessment. Community‐
cancer centers should have good referral networking with hospitals with higher specializations.
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Specific for the growing needs of targeted therapy, according to the most recent guidelines,
facilities should have the capacity to provide mutation testing to patients within two weeks.
In regards to the adherence to treatment guidelines by the clinicians, our study supports the
need to ensure all eligible patients are offered evidence‐based treatments. Findings from our
study, however, should not be interpreted as a ‘one‐size fits all’ approach. The application of
existing guidelines should take into account patients’ characteristics, clinical conditions, and
preference; aligned with personalized medicine and patient‐centered care.
Efforts should be made to address barriers to the utilization of guidelines‐based treatment.
From clinician' side, several issues could hinder the adoption of those guidelines. Clarity,
feasibility, as well as clinicians’ trust of the guidelines, are among important factors that could
determine whether or not clinicians implement the guidelines. As IOM has pointed out, there is
great variability in the quality of existing clinical guidelines in cancer care. 50 Robust evidence is
needed to convince clinician to adopt the clinical practice guidelines, especially in diseases with a
large uncertainty of the risk and outcomes, such as SCLC. Healthcare providers should ensure
effective clinician‐patient communication to convey evidence on the benefit of guideline‐
recommended treatment to the patients during treatment planning.
Specifically for elderly patients, there is a need to improve the adoption of evidence‐based
treatment to leverage the reduction of lung cancer deaths as the elderly accounts for about two‐
thirds of the patient population. Higher toxicities and comorbidity burden often preclude them
from receiving standard treatment.102 Although multiple studies have reported a higher toxicity
rate among elderly patients, age alone should not be the basis for treatment decision. More
recent evidence suggests that the elderly population could obtain the same survival benefits from
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standard therapy as their younger counterparts.106,107 Therefore, more efforts are needed to aid
physicians in determining patients’ eligibility for intensive therapies.
Studies on lung cancer outcomes should not overlook the fact that smokers are not the only
population that suffers from lung cancer. Abundant evidence points to the importance of
occupational and environmental risk factors for lung cancer, other than tobacco smoking. The
clinical setting has started to observe changes in the proportion of lung cancer patients by
smoking status. A hospital‐based study from three diverse institutions in the US showed that the
proportion of never‐smoker among lung cancer patients increased from 8.0% in the period 1990–
1995 to 14.9% in 2011–2013.135 Whether or not the changes represent an increasing incidence of
LCINS, or merely resulted from a declining smoking prevalence, remains a question. Nevertheless,
the importance of never‐smokers in the lung cancer landscape is worth noting.
The limited survival benefit among never‐smokers with lung cancer found in this study points
to the need to ensure that this group of patients receive effective treatments. Previous studies
have identified that a large proportion of never‐smokers with lung cancer present with gene
mutations, particularly EGFR mutation. Since multiple targeted therapy agents have been proven
effective for some of the gene mutations and approved by the Food and Drugs, it is imperative to
improve access to molecular testing, followed by targeted therapy.
As in ever‐smokers, early diagnosis also an issue in never‐smokers, which might reduce their
chance for a better prognosis. In our study, for example, 41.3% of LCINS patients were diagnosed
at an advanced stage. Early diagnosis problem in LCINS is compounded by the fact that many
LCINS cases are either asymptomatic or have non‐specific symptoms, and thus they are more
likely to be diagnosed through incidental detection. 136,137
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Although previous studies do not show the effectiveness of lung cancer screening among
people without a history of heavy smoking, we believe that there are certain groups of the never‐
or non‐smoking population that could benefit from lung cancer screening, for example, a
population who are exposed to environmental or occupational risk factors for lung cancer, other
than active tobacco smoking. Therefore, it is imperative to increase public and clinical community
awareness regarding the risk of lung cancer in never‐smokers, especially among the high‐risk
population. Increased awareness can be expected to lead to patients seeking health care early,
which could potentially lead to the disease being diagnosed at an earlier stage.

5.3 Future Directions
Our findings highlight the importance of thorough assessment prior to definite treatment without
compromising patients’ outcomes, rather than simply meeting the benchmark of providing
treatment within a specified time. However, the question of ‘how long can a patient safely wait
for treatment?’ needs to be addressed through empiric data of the critical time points that could
predict unfavorable outcome for patients. This information will be useful to revisit existing
guidelines pertinent to the timeliness of cancer care. Future studies also need to examine the
association between time‐to‐treatment and outcomes other than mortality that are also
meaningful to patients, such as progression‐free survival, quality of life, and psychological
distress. These immediate outcomes might offer a better understanding of how the health system
should be delivered to maximize patients’ benefits.
Methodological approaches for studies addressing treatment delay could be challenging, as
it would not be ethical to conduct an experimental study by assigning patients in delayed and non‐
delay groups. However, given the potential problem with confounding by severity, future
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prospective studies with detailed clinical information are warranted. One potential problem that
may arise from prospective studies in this field is the Hawthorne effect, in which clinicians may
change their behavior (in this case, toward expediting the treatment initiation) due to being
observed. However, given there is no formal established guidelines on time‐to‐treatment in the
US and the fact that multiple studies did not show an association between treatment delay and
increased mortality, bias due to the Hawthorne effect may not be of a big concern. Nevertheless,
future studies should be designed to minimize this bias. For example, by random sampling or by
enrolling patients periodically and mask the sample selection from the clinicians.
In regards to adherence to treatment guidelines, we identified gaps in the understanding of
the reasons why guideline‐recommended therapy was not included in treatment planning in some
patients, even after excluding cases with contraindications. Further research is needed to
understand patients’ reasons for refusal to identify system‐based barriers, as well as factors that
lead to guideline non‐adherence from the provider side, such as acceptance of guidelines and lack
of resources.
The gradual decline of smoking prevalence might lead to an increased proportion of never‐
smokers among lung cancer patients in the future. Reducing the incidence and mortality of never‐
smokers with lung cancer might be the next challenge in overcoming the overall burden of lung
cancer. Research opportunities in this area include understanding specific risk factors for LCINS,
early diagnosis for high‐risk population, and identify possible missed opportunities in which
eligible patients do not receive potentially effective treatment.
In general, studies among never‐smoker population provide the opportunity for a better
understanding of the etiology of certain diseases, not just lung cancer, without being confounded
by the damaging effect of chemical substances in tobacco on the cellular system. Molecular
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epidemiologic studies might offer a useful approach to overcome some of the methodological
challenges in researching occupational and environmental exposures specific to the Veterans.
Also, since early diagnosis is a significant challenge in lung cancer, future studies can help identify
existing biomarkers or develop risk prediction models to help detect lung cancer in high‐risk
populations. One of the key factors for improving the survival of never‐smokers with lung cancer
is through ensuring access to molecular testing and targeted therapy for patients with advanced
stage cancer. Future studies can focus on examining the utilization of molecular testing and
targeted therapy in the VA health system.

5.4 Study limitations
Findings from our studies should be interpreted in light of several limitations. The main limitations
are associated with the nature of the observational study and secondary analysis of registry data.
We could not rule out the possibilities of confounding effects from unmeasured variables. In
Chapter II, we have described how ‘confounding by severity’ might affect our results in the first
study. Confounding by severity is a major problem in clinical research, especially in observational
studies. In general, stratification or use of disease severity score are among the approaches that
can be employed to handle confounding by severity, as demonstrated by Torring et al. in a study
on diagnostic delay.138 For our study, we have stratified our analyses by stage at diagnosis. We
hypothesized that, to some extent, cancer stage at diagnosis represents a disease severity score
since it is a composite measure of the extent of the tumor (T), the extent of spread to the lymph
nodes (N), and the presence of metastasis (M). Our stratification by cancer stage, however, might
not be sufficient to eliminate the effect of other confounders. It is likely that there are other
clinical variables more influential to the decision of time‐to‐treatment for lung cancer patients
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that were not included in our study (such as performance status, type of comorbidity, and
symptom burden). This is the key limitation of our study, which we worked to address by
performing a subset analysis in early‐stage patients who received surgery alone. We considered
this group as relatively homogenous with respect to their clinical conditions. That way, we were
able to show the adverse effect of extended time‐to‐treatment on survival.
Another approach to handle confounding by severity is through the propensity score method.
However, due to the absence of more detailed clinical information, we believe that applying the
propensity score approach in our study would not have dramatically altered the results, and could,
in fact, resulted in matched cases which do not have similar severity. Although we could not rule
out potential confounders in our study, our findings generally follow the clinical logic in the
association between time‐to‐treatment and survival.
The NCDB has limited information to explain why patients do not receive guidelines‐
recommended treatment. The NCDB records indicate that, in most patients who did not receive
adequate treatment, the guideline‐recommended treatment was not included in their treatment
plan. The NCDB’s guideline for data reporting lists the exclusion reasons as either: 1) treatment
not usually recommended for the disease; and/or 2) patient decided to undergo other therapeutic
option(s). However, we were unable to verify the actual reason for exclusion of any therapy from
the treatment plan.
Our analysis of VACCR data poses limitations on the generalizability of the findings. Our study
population may not be generalizable to all US veterans. Veterans who are enrolled in the VA
health benefit tended to have lower socio‐economic status and poorer socio‐economic and health
conditions.81 Another limitation was the use of self‐reported smoking status, which is subject to
misclassification. However, although of a small size, a study validating smoking status among
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participants in a Lung Cancer Screening Trial showed high consistency between the self‐reported
status and urinary cotinine test (κ = 0.85, P < 0.001). 139 In addition, given the percentage of current
or former smokers is high among veterans, we believe misclassification of smoking status would
not affect our results.

5.4 Conclusions
In summary, this dissertation has addressed some of the gaps in the current knowledge of
prognostic factors among lung cancer patients. This dissertation points to the importance of
alleviating system‐based barriers that could contribute to unnecessary treatment delay, sub‐
standard care that does not adhere to the clinical practice guidelines, and missed opportunities
in providing targeted therapy for never‐smokers with lung cancer. These are important aspects
that should be continuously addressed to improve patients’ outcomes, along with other scientific
innovations in the fight against lung cancer.
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APPENDICES
Appendix A: Lung cancer staging
Table A1. Definitions for T, N, and M Descriptors of the 8th Edition of the Classification of Lung
Cancer
Description
T: Primary Tumor
TX

Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in
sputum or bronchial washings but not visualized by imaging or bronchoscopy

T0

No evidence of primary tumor

Tis

Carcinoma in situ:
 Tis (AIS): adenocarcinoma
 Tis (SCIS): squamous cell carcinoma
Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without
bronchoscopic evidence of invasion more proximal than the lobar bronchus (ie, not in the
main bronchus); the uncommon superficial spreading tumor of any size with its invasive
component limited to the bronchial wall, which may extend proximal to the main bronchus,
is also classified as T1a

T1

T1mi

Minimally invasive adenocarcinoma

T1a

Tumor 1 cm or less in greatest dimension

T1b

Tumor more than 1 cm but not more than 2 cm in greatest dimension

T1c

Tumor more than 2 cm but not more than 3 cm in greatest dimension

T2

Tumor more than 3 cm but not more than 5 cm; or tumor with any of the following
features (T2 tumors with these features are classified T2a if 4 cm or less or if size cannot be
determined and as T2b if greater than 4 cm but not larger than 5 cm):
 Involves main bronchus regardless of distance to the carina, but without involving the
carina
 Invades visceral pleura
 Associated with atelectasis or obstructive pneumonitis that extends to the hilar region,
either involving part of the lung or the entire lung
T2a

Tumor more than 3 cm but not more than 4 cm in greatest dimension

T2b

Tumor more than 4 cm but not more than 5 cm in greatest dimension

T3

Tumor more than 5 cm but not more than 7 cm in greatest dimension or one that directly
invades any of the following: parietal pleura (PL3), chest wall (including superior sulcus
tumors), phrenic nerve, parietal pericardium; or associated separate tumor nodule(s) in the
same lobe as the primary

T4

Tumors more than 7 cm or one that invades any of the following: diaphragm, mediastinum,
heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina;
separate tumor nodule(s) in a different ipsilateral lobe to that of the primary
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Table A1. Definitions for T, N, and M Descriptors of the 8th Edition of the Classification of Lung
Cancer (cont’d)
Description
N: Regional Lymph Nodes
NX

Regional lymph nodes cannot be assessed

N0

No regional lymph node metastasis

N1

Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and
intrapulmonary nodes, including involvement by direct extension

N2

Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)

N3

Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral, or contralateral
scalene, or supraclavicular lymph node(s)

M: Distant Metastasis
M0

No distant metastasis

M1

Distant metastasis

M1a

Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant
pleural or pericardial effusion; most pleural (pericardial) effusions with lung cancer are due
to tumor; in a few patients, however, multiple microscopic examinations of pleural
(pericardial) fluid are negative for tumor, and the fluid is nonbloody and is not an exudate;
where these elements and clinical judgment dictate that the effusion is not related to the
tumor, the effusion should be excluded as a staging descriptor

M1b

Single extrathoracic metastasis in a single organ and involvement of a single distant
(nonregional) node

M1c

Multiple extrathoracic metastases in one or several organs

Abbreviations: TNM, Tumor Nodule Metastasis.
Reprinted from Rami‐Porta et al., 2017(Rami‐Porta, Asamura, Travis, & Rusch, 2017) with permission from John Wiley
and Sons.
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Table A2. Stage Grouping of the 8th Edition of the TNM Classification
Stage
Occult carcinoma
0
IA1
IA2
IA2
IB
IIA
IIB

IIIA

IIIB

IIIC
IVA
IVB

T

N

M

TX
Tis
T1mi
T1a
T1b
T1c
T2a
T2b
T1a, b, c
T2a, b
T3
T1a, b, c
T2a, b
T3
T4
T4
T1a, b, c
T2a, b
T3
T4
T4
T3
T4
Any T
Any T
Any T

N0
N0
N0
N0
N0
N0
N0
N0
N1
N1
N0
N2
N2
N1
N0
N1
N3
N3
N2
N2
N3
N3
N3
Any N
Any N
Any N

M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M1a
M1b
M1c

Abbreviations: TNM, Tumor Nodule Metastasis; T1mi, minimally invasive adenocarcinoma; Tis, tumor in situ.
Reprinted from Rami‐Porta et al., 2017(Rami‐Porta et al., 2017) with permission from John Wiley and Sons.
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Appendix B: Unadjusted survival plots by treatment adequacy in patients with SCLC

Fig B1. Unadjusted survival plot by treatment adequacy in LS‐SCLC patients

Fig B2. Unadjusted survival plot by treatment adequacy in ES‐SCLC patients
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